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Due to growing old age population and increase in chronic diseases at all the ages
across the world, there is an opportunity for Biomedical device companies for a vital
investment and address the problems by introducing risk free, effective, and safe devic-
es into the market. Presently, the market for Biomedical Wearable and Implantable de-
vices is in high demand due to wider applications and advance in computing algorithms
in Medical industry.
The current thesis has been focused on commercialising and quality requirements of
Biomedical Wearable and Implantable devices by understanding the market require-
ments and increase in global demand for quality devices. In order to manufacture an
effective Biomedical device, manufactures have to establish quality management sys-
tems in every phase of product development phase to produce safe and effective devic-
es, and meet the requirements of regulatory authorities who in turn are answerable to the
public. These Biomedical devices can extend and give quality life to the patient suffer-
ings.
Though companies see a profitable business for these innovative Biomedical devic-
es, stringent requirements and longer approval time process from regulatory authori-
ties are making the Biomedical device companies to rethink to enter the market in these
Biomedical devices. Moreover, regulatory authorities should consider adopting the
global nomenclature and standards due to increasing global demand supply chain man-
agement for these devices.
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11. INTRODUCTION
1.1. Motivation
The motivation for doing thesis in this particular subject is an idea gathered during my
work experience during my tenure as ERP consultant for GE Healthcare where I have
experienced  quality  systems  of  GE  Healthcare  software  system.  As  per  the  Food  and
Drug Agency(FDA) requirements the GE Healthcare Company should confront the
software system in regards to quality requirements. This provided me an insight of the
regulations  and  quality  requirements  of  FDA to  a  Healthcare  company.  This  was  also
my motivation point to take up my master degree course in Biomedical Engineering
field while Industrial Management as minor field. I have envisaged learning the regula-
tions in Medical devices and implementing qualities to confront the regulatory authori-
ties and improve the quality system internal to the company.
1.2. Healthcare and Medical Industry
Medical field has been diversified(as shown in figure 1.1) and technologies from other
fields have been implemented in Medical and Healthcare industries which have been
evolving by inventing new technologies and increasing the life expectancy and quality
of life of the public. But, the major concern for these technologies has been with safety
issues, because of which regulatory bodies have been formed over time across countries
for the benefit of the public health. The purpose of the regulatory bodies is to follow the
product development process of the companies and make sure that they implement the
quality requirements as governed by the regulatory bodies. Table 1.1 shows vari-
ous(important) regulatory bodies across word-wide, while figure 1.2 shows the
Healthcare markets in the world.
Table 1.1. Regulatory bodies across world-wide [1].
Country Regulatory Agency
USA
Europe
Japan
China
Brazil
FDA
EU Notified Bodies and National Competent Authorities
PMDA
SFDA
ANS
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It is therefore important for the companies to thoroughly gather the necessity re-
quirements of the regulatory bodies to market the products from the beginning of the
product development process. Adhering to the requirements of the regulatory authorities
can reduce a stipulated amount of time and expenses incurred during the course of
product development.
Figure 1.1. Diversification of Medical field [2].
Figure 1.2. Competitiveness facts and figures(2007) [1].
1.3. Biomedical Wearable and Implantable Devices
Medical industry is a vast subject and involves pharmaceutical, drug delivery, Medical
equipment’s, Medical orthopaedics, Medical support, Medical ambulatory interests.
Further due to increase in the ageing population who need assistance, and increase in
number of chronic diseases who require continuous monitoring/treatment, companies
have found new ways to give a better life and rapid diagnosis/treatment by focusing on
Wearable and Implantable devices.
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Before explaining the definition of Biomedical Wearable and Implantable devices it
is better to have insight of the definition of Medical device. FDA states “a Medical De-
vice is an instrument, apparatus, machine, contrivance, Implant, in vitro reagent, or oth-
er similar or related article, including a component part, or accessory which is:
x recognised in the official National Formulary, or the United States Pharmacopoeia
x intended for use in the diagnosis of disease or other conditions, or in the cure, miti-
gation, treatment, or prevention of disease, in man or other animals, or
x intended to affect the structure or any function of the body of man or other animals,
and which does not achieve its primary intended purposes through chemical action
within or on the body of man or other animals and which is not dependent upon be-
ing for the achievement of any of its primary intended purposes”. [3]
Any Biomedical Wearable device is a device that is being worn by a person and as-
sists in Medical monitoring or support over a long period of duration. The Wearable
device is non-invasive which is an accessory or is embedded within the garments of the
patient. These devices have physiological sensors which can process the data through
complex algorithms and can be transmitted through wireless communication systems.
The receiver end can be doctors or Healthcare monitoring units where they can study
the subject’s data and provide treatment whenever required as outpatient units. These
Wearable devices are small in size, light in weight, unobtrusive, and basically designed
for patients with prolonged chronic diseases or disability or people with congenital dis-
order which are designed to give real-time feedback to the doctors for Medical deci-
sion/assistance [4].
Further Wearable devices can be classified into Medical care equipment (termed as
Medical device data systems by FDA) [5] and home Health and consumer devices, cur-
rent thesis focuses on Medical care equipment as these devices should pass the regulato-
ry compliance for marketing the device and require physician intervention. Since, home
health and consumer devices do not require any physician intervention and these devic-
es do not require tedious process of compliance of the regulatory system, however they
are regulated for safe use by the public.
Figure 1.3. Examples of Medical care  vs. home Health Wearable devices.
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Biomedical Implants are artificial devices which are in contrast to transplants which
are manufactured to replace a missing biological structure, support a biological struc-
ture,  or  enhance  the  operation  of  an  existing  structure.  In  current  thesis  the  following
Implantable devices have been discussed;
x general Implants
x Active Implants with medicinal products
x Active Implants for clinical monitoring/treatment (e.g. pacemakers)
x Implants with drug delivery devices
Figure 1.4. Examples of Biomedical Implantable devices.
1.4. Safety and Compliance
Though articles with advanced Medical technologies have been published over period
of time, many research works could not enter the market due to failure in product devel-
opment process and risk of the devices for the public health. The regulatory agencies
make sure that the Medical devices available in the market have more benefits than
risks, so the public can trust on these regulatory bodies in terms of buying the device to
be used safe enough. Therefore, these bodies have to assure the public that the related
technology or Medical device is safe upon application for treatment or diagnosis.
1.5. Research Method
Though current thesis is based upon commercialisation and quality requirement of Bio-
medical Wearable and Implantable devices, I have started with literature review of pro-
cess related to FDA. Though going through each and every step of FDA was tedious,
time  taking,  and  confusion,  I  had  an  overview  of  the  FDA  process.  Further,  I  started
reading the quality requirements of some of the Implants which got approved through
both Pre-Market Application(PMA) and 510(k) approval. This gave me further hint of
quality requirements on Medical devices.
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The next step was to concentrate on commercialisation of the Medical devices into
the market. I have gone through the book “Commercialising successful Biomedical
Technologies” written by Shreefal S. Mehta which is based on FDA process. The author
thoroughly explained about the contemporary methods and process used by various
companies  to  get  approval  from the  FDA and also  highlights  different  ways  for  reim-
bursements invested by the companies by involving the stakeholders from the start of
the product development. Shreefal S. Mehta in his book stated that companies trying to
market their product in USA have to involve with Medicare, insurance companies, hos-
pitals and other 3rd parties so the product/device is given preference or the device
should be placed in the Healthcare provider catalogues for the treatment.
Since companies market the device differently depending on the organisations val-
ue-chain there is no particular commercialisation process for marketing the Medical
device. Hence, I followed the book “Biomedical Technology Assessment: The 3Q
Method” written by Phillip Weinfurt(Marquette University). The three question(3Q)
Method basically gives hindsight about how a company which is developing a product,
or an organisation which is buying the product should answer the following three ques-
tion: “Is it Real?, Can We Win?, and Is It Worth It?”
Once acquiring knowledge of commercialisation process in USA and quality re-
quirements of the Medical devices with respect to FDA, I moved on with Europe Union
Medical Device Directives(EU MDD) to have an basic understanding of the processes
involved between EU notified bodies and FDA agencies. Further, thinking of future
prospective trade of inter-continent businesses, I had a detailed view on International
Medical Device Regulatory Forum(IMDRF) and World Health Organisation(WHO)
documents. The sole purpose is to understand how the IMDRF can minimise the com-
pliance or regulatory works for companies intending to market globally. The common
goal of IMDRF is to focus on common regulatory works that a company has to follow
to market their devices across continents or countries.
1.6. Goals
The  goal  of  the  current  thesis  is  to  analyse  and  layout  the  commercialisation  process
involved in marketing a Biomedical Wearable and Implantable devices(through same
process is used for other Medical devices) and to define quality requirements of these
devices. There is no single correct process that a company follows, but I have general-
ised the basic approach for commercialising the Biomedical Wearable and Implantable
devices. During commercialisation process companies have to involve with different
stakeholders, internal and external to company. Though product development is tip of
the iceberg, external stakeholders play a vital role in making companies to generate their
revenues. Further, the current thesis focusses on quality requirement for these Biomedi-
cal devices in order to achieve the feasible final product and comply with the norms of
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the regulatory bodies. In addition, the thesis work focuses on the good practices that are
mandatory for any Medical device companies to endorse their final product and get ap-
proved from regulatory agencies for marketing.
1.7. Document Structure
While the objective of the thesis has been discussed in chapter 1, the remainder of thesis
is organised in the following way. Chapter 2 presents the future market growth and ap-
plications of these Biomedical devices. Chapter 3 covers different product development
and commercialisation stages, including future scope of demand-based manufacturing
and Unique Device Identification(UDI) for global traceability of Medical devices. In
chapter 4 various quality requirements of Biomedical Wearable and Implantable devices
to be adopted by manufactures’ have been discussed extensively, while chapter 5 dis-
cusses the good practices to be maintained by the manufacturers’ during product devel-
opment stages so the results are accurate, repeatable, trustable, and efficient. Further in
chapter 6, the EU vs. FDA regulatory affairs, the future role of IMDRF, future complex-
ity in applications of these devices, and challenges in Biomedical Wearable and Im-
plantable devices have been briefly discussed. The last chapter summarizes the work
that he been done and gives a hint of challenges that exists.
72. MARKET AND APPLICATIONS OF BIOMEDI-
CAL WEARABLE AND IMPLANTABLE DEVICES
The applications of Biomedical Wearable and Implantable devices are in numerous and
have increased the life expectancy and given quality of life to the public by generating
accurate data to the clinicians. Though there are certain risks of using these devices, the
benefits are more when compared to risks associated with these devices. Over the years
companies have used advanced technologies in design processing, enduring risks for
marketing, increasing the life cycle of the device, biocompatibility nature of the Im-
plantable devices, using microchips for monitoring and diagnosis  of the patients, and
increasing  the  quality  of  life  of  the  public.  In  the  past,  there  were  failures  associated
with the Implants, but companies through learning process from the predicate devices
and capital spending in R&D department, have definitely changed the scope of the Med-
ical technologies, earned the trust of regulatory authorities and public, and found better
solutions for both the public Health as well as profits.
2.1. Biomedical Implantable Devices
2.1.1. Biomaterial Implants
Biomaterial is a synthetic material which is biocompatible, non-toxic, and non-
carcinogenic which has physical and mechanical characteristics, can be degradable or
non-degradable material to be used as augmentation or replacement of body tissues.
Biomaterial have found applications in orthopaedics, cardiovascular applications, dental
applications, wound healing purpose(sutures), opthamalics, gastrointestinal, plastic sur-
gery, and drug delivery systems. Most of the ingredients used in Biomaterials are met-
als, polymers, ceramics, and composites. The market for cardiovascular is expected to
grow at Compound Annual Growth Rate(CAGR) of 14.5% from 2009 to 2014, where
the market value in 2008 was $9.8billion. The overall Biomaterial Implant industry is
going to be worth $22.8 billion in USA with CAGR of 13.6%, while in EU $17.7 billion
with CAGR of 14.6% and global worth of US $58.1 billion by 2014[6].
2.1.2. Orthopaedic and Dental Implants
Orthopaedic Implants are most commonly used in patients who are suffering from oste-
oporosis, osteoarthritis, bone cancer, and patients who have undergone acci-
dents/trauma. Osteoporosis is most common in old people above age 50, and due to
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growing old age population world-wide which is estimated to be 31.4% by 2020 in EU-
27 and 25.3% by 2020 in USA[7]. There is huge demand for orthopaedic Implants and
companies  have  to  deliver  risk  free  and  safe  Medical  devices.  Globally,  one  in  every
three women, and one in every five men above age 50 suffer osteoporosis, of which
33% of these adults who suffer from hip fractures are disabled in year and are depend-
ent for support to continue their normal life[8].
In USA it is estimated that in the year 2013, around 3,010 patients shall be diag-
nosed with bones and joint cancer which represents 0.2% of all cancers[9] of which
1,440 shall die. Though this is a smaller figure the estimated rate shall increase in forth-
coming years. Patients suffering from bone cancer(primary bone cancer) have to go
through enormous side effects through chemotherapy process and other surgical meth-
ods. If the bone cancer resides in the areas of arm, shoulder, leg, or hip the surgeon can
decide to operate “limb sparing surgery”[10] where the affected area is removed and is
replaced by orthopaedic Implant.
Another area of application is use of orthopaedic Implants for patients who have
gone through accidents/trauma, where there is requirement for the fixation of the bones
to continue their  normal physical  activity.  Moreover,  surgeons also use screws, plates,
and other accessories for the treatment of fracture encountered in the trauma.
Dental Implants are used world-wide for better appearance, improved speech; ease
in  eating,  higher  self-esteem,  and  for  oral  health.  The  industry  of  dental  Implant  shall
rise from $3.5 billion in 2011to $7 billion in 2020 with CAGR of 10%. It is estimated
that penetration of dental Implants is going to rise by 25% to 30% of USA population
by the year 2020[11]. Most of the dental implant industry is used for cosmetic changes
of facial expression.
2.1.3. Active Implants
Active Implants are biocompatible Medical Implants that are embedded with chips
which are used for treatment, or diagnosis on implanting it inside the body using bio-
feedback system. The modern applications of the active Implants are monitoring of dia-
betics, treating eye disease such as glaucoma, neuro-simulator for patients with nervous
disorders, and are used in heart rhythm management[12]. For example, in USA alone
325,000 deaths occur due to Sudden Cardiac Arrest(SCA) [13], this can be prevented by
using implantable defibrillators. The future of active Implants involves implantable
nano-robots or sensors which transmit data through wireless communication with the
physician to generate data of the state of patient and the Implant itself. Further, research
work is going on in the area of active implants where the biocompatible sensors can be
implanted inside the body in order to detect the cancer at early stages.
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2.MARKET AND APPLICATIONS OF BIOMEDI-CAL WEARABLE AND
IMPLANTABLE DEVICES
2.2. Biomedical Wearable Devices
Applications of Biomedical Wearable devices have just started to boom due to advance
in microelectronics, wireless transmission network, and advance computing algorithms
in Medical industry. Biomedical Wearable devices can be used for the patients who are
suffering from chronic diseases such as heart, epilepsy, related to nervous system, dia-
betic’s detection, pulmonary measurements, and rehabilitation purpose.  For example,
patients suffering from weak muscles or paralysis can use Wearable device to trigger
the impulse for the movement of the muscle. It is estimated that 1 in every 25 children
aged between 6months to 5years experience febrile seizures[14], application of Weara-
ble devices on this children can alert the parents or care givers as they need regular
monitoring. The sensors are mounted on the designated area of the body, this reads the
information  and  transfers  the  data  through  wireless  transmission  to  the  clinicians,
healthcare units, or alert the care takers for the action to be taken on these patients[15].
In addition, Wearable devices can be used in ambulance services to monitor the key
functioning of the patients and this data can be transmitted to hospitals so that the doc-
tors are ready to serve the patient quickly soon after the arrival of the patient. Further,
future active Implants can be connected to these Wearable devices for transmitting the
data and controlling the parameters of the implanted active device.
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Commercialisation of a Medical device is a product development process where the
product is released into the market for the benefit of the society to diagnose/treatment
and to cure the illnesses, and generate revenues to the company. Product development in
Medical industry starts with the research in customer requirements or market specifica-
tions. More than the time invested in creating a new product, most of the companies do
analysis or survey to estimate the scope of the device. The analysis should include de-
mographics, survey of how many people are suffering from the disease or need of the
product, and how well the product can be distributed through various modes of distribu-
tion. The final step in product commercialisation is where most of the companies spend
money in advertising, sales promotion, and other marketing efforts.
The three key steps in commercialisation of a product are:
x to look into the many product development ideas and choose one or two products
that can benefit the company both in short-term and long-term
x to devise a proper plan and have stage-wise objectives(checkpoint clearance) and
analysis in further developing the product
x to involve all the stakeholders in early stages of the product development. Further, it
is important that the customers participate in the product development process using
prototypes
The commercialisation process should consider:
x decision on the release time of the product(studying the competition and patent)
x region of release of the product
x target group where the product should be released through research and test market-
ing the device
3.1. Modern Healthcare Industry
Health sector is one of the most rapid growing industries in the world. In modern world
many unknown diseases have been diagnosed and various medicines have been invent-
ed for cure. But human science is not so easy to understand and it takes time to recog-
nize the cause of the disease and then invent the cure for the disease. Modern medicines
with advanced technologies have allowed researchers to invent medicines to cure forth-
coming diseases despite a huge challenge in risks associated with the use of the product.
Companies invest time and money in development of Healthcare industry as the profits
11
3.COMMERCIALISATION
generated in Medical industries are enormous. Current trend shows that USA has largest
Healthcare service sector with revenues approximating $1.75 trillion while the market
for Medical device industry sector accounts $110 billion and is estimated to grow due to
rapid development in technologies and increase in population with diseases[16].
3.2. Concept of Commercialisation
For Biomedical Wearable or Implantable device companies, the figure 3.1 indicates the
basic paradigm life cycle of product development from idea to commercialisation of the
product. The propulsion to commercialise the device is invention/idea through market
trends or customer needs. Secondly, in order to make the invention/idea to be marketa-
ble, companies have to plan if the product is viable and suits the strengths of organisa-
tion to build and sell the product. Later, organisations have to make decisive strategies
to plan the product development process which involves business model, personnel al-
location, financial plans, prototypes, future development strategies, pre-clinical trials,
clinical trials, compliance to regulatory laws, manufacturing, distribution, and stake-
holders.
Figure 3.1. Product development check point’s [17].
3.3. Market Research
Market research is the genesis for understanding the requirement to commercialise the
product as many innovative Medical technologies have failed to make an impact in the
market. The process of product development should be started with understanding of
requirements of the product as per the market needs. For organisations to make the in-
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vention  commercialisable  they  have  to  define  the  market  potential  of  the  new  idea  to
convince the management or sponsors in their business plan. The market research helps
to identify: the market, opportunity to new invention, product characteristics, competi-
tors, and projection of sales, profits, and pricing. Finding early market size of the new
invention can help the management to go forward with production or to drop the idea of
new invention to commercialise.
3.3.1. Market Research Methodologies
Medical market research information for Biomedical Wearable and Implantable devices
can be gathered using primary or secondary information. Primary information can be
gathered by going through past records of predated products and listing down the suc-
cess and failure of each of the products. For example for hip fracture, the company can
list own all the available treatments and can chart down the best procedures adopted, the
cost of the product, the cost for treatment, and adverse side effects or deaths using those
technologies. The other approach is testing of prototype using simulation and advanced
techniques by involving the customers, clinicians, and other stake holders. This ap-
proach can help the companies to define design parameters and spread knowledge to the
public. In case of Wearable devices, users can be asked to use the prototype technology
for observation and self-assessment.
The secondary information for research can be found at public sources which in-
clude reports published by regulatory agencies, notified bodies, and physician associa-
tions. Other sources include hospitals, insurance companies, internet search, commercial
research sources especially marketing the statistics for profits, and journals.
3.3.2. Market Segmentation Approach
Once the market statistics and requirements are recorded the next step is to segment the
market in terms of demographics and technology competent. For instance, companies
have to predict the reachable population for device, known as sizing of the market. The
sizing of market should be in numbers, and should consider the similar products and
competitors in the market. For example, aging population across Europe which is esti-
mated to be 31.4% by 2020 in EU-27 and 25.3% by 2020 in USA[18] respectively re-
quires lot of attention towards old age problems, which means lot of scope for compa-
nies marketing in Biomedical Wearable and Implantable devices. In addition, compa-
nies have to list down the market size in terms of value i.e., $100million, or $1billion or
greater. Then the companies have to chart down the list of existing treatments in the
market, treatments that are niche, and the survival time period of the new invention be-
fore other new treatments race into the market.
In segmentation approach companies have to also consider factors such as targeted
age, pricing, marketing geographic region, stage of illness where the new invention can
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be introduced to the patient, market acceptance, risks associated with the product, hur-
dles to introduce the product, treatment costs at various geographies, and growth of the
product. Though it is difficult to predict the scope of future of the product, statistics can
give hint for companies using historical data.
3.3.3. Market Assessment Techniques
SWOT Analysis
Considering the market position and other competitors in the existing market, compa-
nies have to assess Strength, Weakness, Opportunities, and Threats(SWOT). The figure
3.2 lists the SWOT analysis for both Biomedical Wearable and Implantable devices.
Figure 3.2. SWOT analysis of Biomedical Wearable and Implantable devices [19].
PESTEL Analysis
PESTEL stands for Political, Economic, Socio-cultural, Technological, Environmental,
and Legal. When introducing a new product in to the macro-environment manufacturers
have to consider many factors that affect the decisions, market value-chain, and brand
value of the company. Using these factors managers can make appropriate decisions
about the product. Table 3.1 highlights factors that have effects on the product and
company for Biomedical Wearable and Implantable devices.
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 Table 3.1. PESTEL analysis of Biomedical Wearable and Implantable devices [20].
Issue Impact on business
Political
•pressure on  price control
•funding to small organizations
•regulatory policies for implant and Medical wear-
able devices
•aging population agenda
•length of patent protection
•infrastructure for eHealth
•different policies during different regimes of
government tenure
•cross-border business trade impact
•global forum for regulatory compliance
•growing aging population
•loss of revenues to the companies
•pressure to deliver the product
•loss of business due to cutbacks
•cannot introduce the product in developing coun-
tries due to high prices and infrastructure
•recoup the invested money in less time due to
protection of patents
•tax deduction
Economic
•global economic crisis
•government sponsored public care
•insurance companies
•income per capita(individual income)
•pressure from buyers for price reduction
•reluctance from patients to spend on expensive
treatments
•increased pressure from stakeholders to decrease
costs which effects revenues of the company due
to global crisis
•price control by insurance companies and hospi-
tals
Sociocultural
•acceptance of technology in developing world
•acceptance of technology by surgeons and general
practitioners
•awareness of treatment
•increasing aging population
•increasing dental treatments, bone cancers, and
heath diseases
•local ethics
•sales of devices
•easy reimbursement for the company
Technological
•rapid growth of technology
•customized products
•Supply chain management
•well trained personnel’s in advanced technologies
•competition of the similar, predated and advanced
products
•infrastructure for eHealth
•better tools and techniques
•advanced approach to build customize products
•service centres for both patients and doctors
•low impact of sales due to competition
•integration with all stakeholders using
ERP(enterprise resource planning)
•new application products
Environmental
•growing concern to reduce wastes •ecological business
Legislation
•bills passed by governments to Medical device
companies
•death or adverse effects on patients
•change in regulatory affairs
•adoption to change in policies
•compensation to the patients
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Fish-Bone Analysis
Companies can use Fish-Bone analysis(also known as cause and effect analysis) as
shown in figure 3.3 when implementing the New Product Development(NPD) to ana-
lyse the competence within the internal environment. The Fish-Bone analysis helps in
identifying the problem and factors that affect the product development. This way the
companies can discover the problems before the start of development process.
Figure 3.3. Fish-Bone analysis for analysing internal company competence to start a
venture in Biomedical Wearable and Implantable devices [21].
3.3.4. Drivers and Hurdles
In order to establish a well product commercialisation plan, companies have to run
checks on driving forces and hurdles involved in product development and marketing
process. The foremost drivers for Medical Implants are the aging population in Europe
and rest of the developed countries, demand in cosmetic industry, and increasing dental
industry penetration. An increase aging population means a strong market for innovative
products that can increase the life expectancy and physical Health. The second driving
force is investment by government organizations and other venture capitals in Medical
Wearable and Implantable devices. It is estimated that EU grants 20% of the budget for
research, education and training, and transport and energy[22]. In the Medical field re-
search, the Seventh research Program(FP7) which is funded by EU supports the follow-
ing areas: brain research, human development and aging population, major diseases and
disorders, severe chronic diseases, and various other applications[23]. Small and Medi-
um-sized Enterprises(SME’s) who are looking for funding in Biomedical Wearable and
Implantable devices can make proposal to be funded by EU grants.
The other driving force for the marketing of the product is the referral chain in-
volved in making the product available through referral chain system. Companies
should identify the stage where the clinicians can use the device for the treatment. It is
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also important for the companies to identify the referral system of other existing treat-
ments or products in the current market. Using this method companies can define their
own referral chain system during the product development process. A brief referral
chain for hip replacement Implants is shown in figure 3.4. Moreover, implementing
Operating Room Device Technician(ORDT) from the company to assist the doctors
during the transition phase of implanting the device rather physicians depending on
sales representative[24], or advertising programs for the benefits of Wearable device
can be a huge driving factor for the sales.
Figure 3.4. Referral chain of hip replacement Implants.
Another key concept involved in the research is identification of indication for the
Medical device. Indication is defined as the Medical device used for treatment for that
particular disease or stage of the referral chain system. Identification of indication is the
foremost key element during product development and approval from regulatory agen-
cies. As shown in figure 3.5, doctor prescribes Wearable ECG unit to reduce the Length
of Stay(LOS) in hospitals while continuously monitoring the chronic heart pain through
wireless transmission of data. The indication here is chronic heart pain with murmurs.
Figure 3.5. Indication for usage of Wearable ECG device.
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The hurdles in commercialising the Biomedical Wearable and Implantable devices
are delay in getting the product approved by regulatory bodies, repetitive submissions of
documents, and time period to wait for approval in different phases of product devel-
opment etc. Other hurdles include the buying power of the product by Healthcare pro-
viders. These providers which include Health Maintenance Organisations (HMO’s),
insurance companies both public and private, and hospitals can dictate the price terms
and pressurise the companies to cut-off the actual prices. This may adversely hamper
the revenues of the companies for future planning of other product developments.
3.4. Intellectual Property(IP), Patenting, and Licensing
Biomedical device companies have to invest time in finding out if their devices are pa-
tentable before product development process as this may hamper sales of product due to
competition from generic devices. Having patents gives full rights to commercialise the
product in the market with no competition or issuing license to the other companies to
manufacture the product to generate huge profits, and maintain the monopoly in the
business. IP can be registered as patents, trademarks, copyrights, and trade secrets. IP’s
are huge profits to the companies as they can be competitive and withhold other compa-
nies from entering the market using same technology or they can license the IP to other
organizations for profits.
3.4.1. Patenting
There are three types of patents: utility patents, design patents, and plant patents. The
Biomedical Wearable and Implantable devices fall under utility patents. Patents are
granted under three circumstances i.e., the product should be useful, or the product
should be novel, or the product should be non-obvious. Most the Biomedical Wearable
and Implantable devices fall under the novelty or non-obvious due to the reasons:
x Medical Implants are novel due to biocompatibility in nature and have different ap-
plications to both human and animals
x Medical Wearable devices are non-obvious because they use the existing technology
for diagnosis
x Medical Implants are also non-obvious because they are modified versions of pre-
dated devices with new indications
x active Medical Implants are also used in transmitting vital information of the pa-
tients through wireless technology, for instance Wireless Capsule Endosco-
py(WCE)[25]
x Medical Wearable devices might be novel because of the computing algorithms
used for the diagnosis and treatment
x Medical Implants are also novel because they use drug delivery system imbibed in
the device
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A Medical device can be novel if the product is new of its kind when compared to
previous inventions which is also called as prior art[26]. A device is non-obvious if the
product has significant development or changes compared to the existing product. Un-
der Biomedical devices, the devices can be classified in terms of composition of matter,
application or method of treatment(referral chain system), and device or machine used
in production process or diagnosis purpose.
Necessity of Patenting
The patenting gives monopoly to the inventor or any other companies to market the de-
vice and it also prevents other companies or inventors to publish similar claims. It also
gives protection from infringement of the novelty of the device. In order to achieve the
complete right of novelty of the device, inventor or companies have to make sure that
no such prior art exists or have been filed for patenting. Since SME’s through ventures
and funding are involved in innovations they totally relay on patents for profits[27]. It
allows the inventor the freedom to practice rights or licensing of the device to other
companies. Moreover, Biomedical Wearable and Implantable devices apply more than
one technology in the device, the inventors have to buy patents or get license from the
patentee’s to exclusively commercialise their device. But however, the patentee has
certain limitations those include:
x territorial limitations: the patent holds exclusively to the geographical regions filed
x time limitation: the patent holds a time limit of 20years
x limitation in scope: the patent is limited to the indications or application to that par-
ticular disease, treatment, or diagnosis
Process of Patent filing
In USA patent is filled under the United States Patent and Trademark Office(USPTO),
while in EU the patent is filled under European Patent Office(EPO), which covers all
the countries under EU, and also an inventor can patent the invention globally under
World Intellectual Property Organization(WIPO) under Patent Cooperation Trea-
ty(PCT) process where 185 countries have been enrolled. Under WIPO the inventor can
choose the countries where the patent can be valid and allows complete monopoly for
marketing the product[28][29]. The patent filling process is shown in figure 3.6.
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Figure 3.6. Process for filing a patent.
Step1: Once a Biomedical Wearable or Implantable device has been invented, to
claim the patent the inventor or companies should evaluate if the same novelty exists or
if the invention has significant change compared to the existing product.
Step2: The next step is filing a patent (provisional if required more supporting doc-
uments in case of USPTO). The date of filing is called as priority date and it is the most
significant when multiple person’s apply for similar invention in other countries. In case
of filing for EPO the patent application should have information supported in English,
French, or German.
Step3: The patent office shall publish the claim and in due time if any other inventor
claims the same invention then the legal process proceeds.
Step4: The patent office shall award the patent to inventor by reviewing of the in-
vention.
In USA first to invent has proper rights to claim the patent if the inventor has proof
of records and documents, while WIPO follows first to file for patenting. If an inventor
has already filed a patent in one country, and wants to file in some other country and
founds out that someone is claiming the same invention of the device then as per the
PCT act the person filed first in any of the WIPO representative countries(priority date)
can claim the patent rights, also called as priority rights. In case of USA, patent filed at
the time of non-provisional patent is priority date.
The inventors have to make sure that the ideas, basic drawings, thoughts, and other
trivial evidence should be recorded as this might be useful in case if more than one
claim exists for the similar product. Also, the language used for application of the de-
vice should be precise and indicative. Even a slight alteration in the language, an inven-
tor can lose the claim. For Biomedical devices the inventor should name proper indica-
tions and usage of the devices. Also, the organisations or inventor should monitor if any
infringement of the invention at regular interval of time throughout the life cycle of the
product until the patent expires.
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For inventors working in universities or research centres, the technology strategic
managers in the university or third party assess the commercial potential of the inven-
tion. The invention is filed for patent rights and in due process approaches a right inves-
tor for the product development, which may take months to years. In case the patentee is
from university, the university receives payments or gratuities from the companies
which are shared among the inventor, and the departments. In USA, according to Bayh-
Dole act the government sponsored inventions are licensed to small businesses.
3.4.2. Licensing
If an invention has to be converted in to commercial business, the inventor or small
companies shall require huge capital for product development and production. Rather
they prefer to license their patents to other bigger companies for mass production and
commercialising the product. The grant of rights can be classified according to exclusiv-
ity  of  rights,  territorial  or  geographic  distribution  of  rights,  and  field  of  use.  Box  3.1
shows different licensing grant of rights that a company can issue.
Box 3.1. Classification of grants of rights to produce and sell [17].
Trademark also helps to place the Medical devices quick in to the shelves of the dis-
tributors or Healthcare units. Smaller companies can exclusively get license from the
larger companies to market the Biomedical Wearable or Implantable devices for a spe-
cific geographical region for commercialising. Moreover, companies outsourcing for
mass production have to share specific aspects of the design and the trade secrets should
not be disclosed as it may affect the sales of product.
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3.5. New Product Development(NPD)
3.5.1. NPD Planning
In Biomedical Wearable and Implantable devices defining the characteristics at the be-
ginning of product development is significant through research, clinical indications, and
identifying customer requirements. Most of the products fail to enter the market due to
non-feasibility in the development stages of the device. While large companies have
special multidisciplinary teams as shown in figure 3.7 to study and review the stages of
product  development,  contrary  to  this  small  companies  have  to  perform extra  work  in
analysing the product characteristics through external sources. It is better to establish a
structured process beforehand to move the product concept towards commercialising the
product more efficiently and in organized manner. Early planning and designing the
processes involved in NPD can:
x reduce the time of approval at regulatory agencies
x increases successful progress of NPD at different stages
x minimise the costs involved
x ensures quality and safety in every stage of NPD an final product
Figure 3.7. Multidisciplinary teams involved in NPD.
The NPD process in Medical industry starts with market research by understanding
the requirements of the customers and doctor specifications. The marketing team should
study the failures and efficacy of the existing products in the market. And based on the-
se details manufacturers have to design and frame the characteristics of the device in-
cluding the indications. The NPD starts with project proposal to convince the manage-
ment or investors for funding as shown in figure 3.8.
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Figure 3.8. Biomedical device project proposal list.
Business strategies should be established either in long-term or short-term. Because
most of the SME’s have very few product lines, building a right strategy and good plan-
ning to extend the product line for different applications can add them a value chain in
that particular Medical device market. The figure 3.9 shows the new product lines using
similar technology but for various other indications. From the figure 3.9, companies
have to release a new product before the existing product enters into matured market.
Competition and innovation are high in Biomedical device industry, companies have
limited time period to earn maximum profits using minimum costs. Further, due to vola-
tile market in Biomedical device industries no single technology can stay long-term in
the market; companies have to decisively start NPD for other applications before the
existing technology expires as shown in figure 3.9.
Figure 3.9. Technology development for line of products to stay alive in the market
[30].
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During the product development cycle, early identification of risks during the design
phase can make the product successful for clearance by the regulatory agencies. Moreo-
ver,  listing  down of  risk  factors  can  be  helpful  during  the  design  and  pre-clinical  trial
phases. Critical milestones should be determined beforehand as it holds the crucial
phase of NPD process. For example in Biomedical Wearable devices, the critical mile-
stones  are  accuracy  and  sensitivity  of  the  device  to  process  the  signal  using  the  algo-
rithm, despite external noise generated by the patients, and for Biomedical Implantable
devices the critical milestone can be biocompatibility and toxicity tests in pre-clinical
trials and no contra-indications in clinical trials. Certain risks associated with Biomedi-
cal Wearable and Implantable devices are listed in figure 3.10. In case of orthopaedic
Implants it is necessary to determine the biocompatibility and wearablity of the device
due to physical activity.
Figure 3.10. Risk factors associated with Biomedical Wearable and Implantable devic-
es.
3.5.2. Killing the Project
Since Medical devices have high risks and costs involved in development stage it is
always better to identify the risks associated beforehand and take decision whether to
kill the project or continue the project by reducing the risks. Sometimes companies have
to kill the project in the early stages of product development than later stages to reduce
the costs incurred. Companies should also consider clinical trials during risk analysis as
it costs millions of dollars for clearance during regulatory confrontation. For example,
Stryker Orthopaedics has to pay for Rejuvenate and ABG II hip patients[31] because
there was risk due to wearing out of metal joints causing and subsequently leading to
corrosion. The reason of withdrawal, metal hip Implants caused severe damage to soft
tissue and bones, because of which FDA has to halt further manufacturing of hip Im-
plants until  proper steps have been taken to re-design[32] and perform further clinical
trials. This is complete failure in terms of costs associated to the companies. The failure
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of hip implant(Stryker Orthopaedics) was because of inadequate design controls and
clinical trials. Failure Mode Effect Analysis(FMEA) and Stage-Gate approach are  anal-
ysis methods to define whether the companies have to quit the project or reassess the
risks and continue the NPD process.
Failure Mode Effect Analysis(FMEA)
FMEA should be conducted early during the product development process during the
design phase, preclinical trial phase, clinical trial phase, and production phase[17].
FMEA analysis identifies the most likelihood failure at each phase of the NPD. The
main elements of the FMEA analysis are severity levels, occurrence of failure levels,
and current controls(detection) of the failures which have a scale of 1 to 10 where
1(easy to detect) means not severe  and 10(not easy to detect) means very severe. Once
listed down, Risk Priority Number(RPN) is calculated by multiplying severity, occur-
rence, and detection. The highest RPN should be given preference and control methods
should be listed down. Similarly each control methods should be listed down for each
failure mode in descending order of RPN[33].
Stage-Gate Approach
Another approach is the Stage-Gate approach which is decision making by evaluating at
the end of each stage, where next stage of development is progressed only after the
clearance of earlier stage[17]. This approach determines if the project has to be
stopped/reassessed or continued to the next stage of NPD. Also combining the FMEA
approach at each stage can solve the problems encountered in developing Medical de-
vices. Once evaluated at each stage, a decision is made whether to move on to next
stage or needs more assessment of device in the current stage or the project should be
killed.
Figure 3.11. Stage-Gate approach for Biomedical Wearable device[17].
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3.5.3. Product Development Process
Product development process of Biomedical Wearable and Implantable devices are
quite different, where the former requires less time for development on contrast the later
requires more time from development to commercialisation of the product due to pre-
clinical and clinical trials. Biomedical Implants are prone to high expenditure and are
heavily subjected to rules and regulations from regulatory bodies when compared to
Wearable devices. The expertise levels of developers are high in Biomedical Implants,
while Wearable devices require integration from different technologies such as textile
technology, mobile technology, electronics, embedded systems, information technology,
software systems, hardware systems, and computing algorithms.
Biomedical Implantable devices
Biomedical Implants are diverse in nature and depending on the risk of the Implant; the
regulatory bodies dictate the extent of safety and efficacy of the device to be approved
for clearance for marketing. Companies have to understand the classification of Medical
devices before NPD process. The average time taken for Biomedical Implant to enter
the market is about 8 years(as seen in figure 3.13), and an Implant with slight modifica-
tion  from already existing similar device can decrease the costs and time taken to enter
the market. During the Biomedical Implant device development process there are many
stages involved as shown in figure 3.12. For Biomedical Implantable devices the aver-
age time for concept and design is up to 12months, for development and pre-clinical
engineering is between 24 to 36 months, for clinical trials it up to 36 months, and for
approval process it is between 12 to 24 months. In case of 510(k), in USA, the 510(k)
notification review can take 3 to 5 months[34].
In Biomedical Implants most of the design is based on the requirements of the cus-
tomers or market driven specifications. Hence at the time of designing the device it is
important to analyse the customer needs or market driven specification, endpoints, and
indications. Before designing an Implant, companies have to spend time in analysing the
success and failures of already existing devices as this helps the design engineers to
prioritise the design where there is huge risk of failure. For example, around 10000 peo-
ple who have used ASR Implants have filed for lawsuit as the design of Johnson &
Johnson hip Implants went wrong and nearly 40% of ASR hip Implants are estimated to
fail within 5 years of time prematurely as the hip Implant life cycle was estimated to be
15 years[35]. During the product development phase, companies have to consider risk
factors, manufacturing process, regulatory laws, maintenance of the records, and adher-
ing to standards (ISO, ASME in USA, CEN in Europe etc.). Also, companies have to
lock the design phase before the clinical trials as this may lead to unambiguity in devel-
opment process. Companies can also expect some capital returns on selling their prod-
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ucts to animal care units once the safety and efficacy in animal subjects are tested in
pre-clinical trials.
Figure 3.12. Biomedical Implant development process.
Figure 3.13. Time and cost development of Biomedical Implantable devices[17].
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Biomedical Wearable Devices
The development process for Biomedical Wearable devices have short span because
most of these devices are used for diagnostic purpose, and these devices need not go for
pre-clinical trials if unless stated by regulatory bodies. The most important phases of
Wearable devices are design phase and clinical trials to determine if the Wearable de-
vice is accurate and the results are repeatable. The time period for development of
Wearable devices are usually between 3 to 8 years(same as in-vitro devices[17]) and
cost associated in phases of product development varies depending on the complexity of
the device and computing algorithms used. Drug companies have already been adopt-
ing(co-developing) of diagnostic devices for the therapeutic purpose(pairing of diagnos-
tics and drugs)[36]. In future, drug companies may adopt Wearable devices for thera-
peutic treatment and because of this the complexity of product development can change
leading to new regulatory laws.
Other aspects to consider while developing Biomedical Wearable devices are:
x ergonomics of use
x wearablity of the device due to exposure to environment
x information handling and processing
x integration of the device data with healthcare unit software systems
x secure data transmission
x power consumption
3.5.4. Ethical Requirements
During the preclinical and clinical trials, all the Biomedical Wearable and Implantable
devices should follow certain ethical requirements which are mandatory for approval of
the device. The ethical boards committee’s include Institutional Animal Care and Use
Committee(IACUC) and Institutional Review Board(IRB).
The purpose of IACUC is to ensure that the animals used for laboratory testing are
properly taken care. The committee shall review the physical wellness of the animals;
only on approval from the IACUC committee the pre-clinical trials should be started.
Some of the protocols include:
x minimisation of pain and distress caused during animal testing
x proper care of both physical and physiological states of animals
x protocols should ensure the decrease in number of animals for testing
Whilst IRB reviews the clinical investigation protocols, and grant permission for the
clinical trials on human subjects. IRB in regular intervals interacts with human subjects,
to ensure the rights of human subjects are protected, and also make sure that the safe
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levels of dosages are used on human subjects. More information about roles of IRB and
IACUC is given in GxP(Chapter 5).
3.5.5. Indications and End Points
Indications and end points play a vital role for clearance of the product by regulatory
agencies. Indication is defined as the disease for which the product is approved. There
might be several indications for the single device but companies have to separately get
approval for each indication and device should be marketed as per the approved label.
End points are the final reports or statistics during the clinical trials due to usage of the
device on human subjects to estimate safety and efficacy. In clinical end points there
might be primary, secondary or composite end points. The primary end points are used
to convince the authorities that the device is safe and better than the existing treatment
methods[37].  It is important to design Biomedical Wearable or Implantable devices
keeping the end points, indications, and customer needs during the NPD process.
Box 3.2. End points for breast Implants and Wearable ECG device.
3.6. Regulatory Compliance Planning
Unlike free flow of electronic gadgets into the market through lenient regulatory laws,
every Medical device has to strictly adapt to the regulatory compliance pertaining to the
country of sales. The regulatory authorities are catalysts who ensure the final product in
market is safe and shows performance as stated by the manufacturer. A Medical device
manufacturer before starting the product development, he/she has to define the Class of
the device according to regulatory compliance. Unable to classify the Medical device at
the start of product development process can lead to killing the project, can make huge
losses to the company, or increase the development process time. Regulatory bodies
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acting on behalf of the countries have classified the Medical device depending upon the
risks  and  application  associated  with  the  device.  This  section  shall  give  an  outline  of
classification of Biomedical Wearable and Implantable devices, and approval process
with regards to FDA and EU regulatory affairs.
3.6.1. FDA Regulatory Affairs
FDA classifies Medical devices under Class I, Class II, and Class III devices. Most of
the Medical Implantable devices fall under category of Class II and Class III. FDA us-
age term for Biomedical Wearable devices is MDDS which was reclassified to Class I
device in 2011 from Class III devices. Manufactures of MDDS devices should adhere to
requirements of Class I device and are not required for PMA approval. The MDDS
should adapt the QSR 820 for good practices[38]. A manufacturer can sell a Biomedical
Implantable device in USA, under 510(k) or PMA approval from FDA. For 510(k) ap-
proval the manufacturer should demonstrate a substantial equivalent device in the mar-
ket that has been marketed before 1976 or a predicate device which was approved
through 510(k) process. If the manufacturer could not find the predicate device, but can
prove that the device has fewer risks and not required to for the prolonged PMA clinical
trials process, the manufacturer can get approval through “de novo 510(k)” process.
Though 510(k) process is shorter on comparison to PMA process, sometimes clinical
physicians or insurance companies or buyers of the device require a strong clinical evi-
dence of the device to sponsor the treatment. Hence, manufacturers of the Implantable
device approved through 510(k) should also perform additional clinical trials to con-
vince third parties and increase in sales of the device. Manufacturers should make sure
that they schedule meetings with FDA at regular time basis during product develop-
ment. It is mandatory to schedule meetings before the start of pre-clinical and clinical
trials. During the scheduled meetings the manufacturer has to submit all the required
quality documents, records, and protocols followed during the product development
phase of the device. Manufacturers of Biomedical Implant should adapt “21 CFR Part
820 quality system regulations(QSR)” as per the quality requirements of Medical devic-
es. While, quality requirements for combinational products has been discussed in GxP
(Chapter 5).
3.6.2. EU Regulatory Affairs
EU system classifies Medical devices under Class I, Class IIa, Class IIb, and Class III.
The Biomedical Wearable and Implantable devices fall under the category Class IIa,
Class IIb, or Class III. Dental Implants and Wearable devices come under Class IIa de-
vices. Classification of device is important for the manufacturer as it defines the con-
formity assessment route through annexes of the Medical device directives. Any com-
pany marketing their device in EU should have CE trademark. If the manufacturer is
outside the EU, it is his/her responsibility to appoint an authorised representative who
can handle regulatory issues. A CE mark is given to the Medical device only after going
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through the conformity assessment done by Notified Bodies (NB) that are hired by the
manufacturers. Manufactures should adhere to the guidelines of Medical device direc-
tives for conformity assessment of Medical devices as shown box 3.3. Many companies
in EU adapt ISO 13485 standards for Quality Management System(QMS). For CE
marking,  manufacturers  of  Class  IIa,  Class  IIb,  and  Class  III  have  to  get  certification
from NB which includes:
x EC Type Examination Certificate (issued during the design phase)
x EC Design Examination Certificate (issued covering design and production phase)
x EC Certificate Full Quality Assurance System
x EC Certificate Production Quality Assurance
x EC Certificate Product Quality Assurance
x Certificate of Conformity (after product has been verified) [39]
For Biomedical Implantable devices having medicinal products, the NB shall review
the importance of the substance governing the application of the device and shall take a
scientific opinion from designated European Medicinal Agency(EMEA) authorities.
EMEA shall review the dosage levels, any modification to the actual substance, manu-
facturing process, and benefit/risk factor. Only once approved from the EMEA of the
use of medicinal product and other quality requirements the NB can give the CE mark-
ing.
Box 3.3. Medical device directive as per EU system.
3.7. Project Management
Project management is important task in controlling the various phases during NPD
process. Project managers have to formulate timelines for every phase and assign per-
sonnel’s, and are responsible that the tasks are being completed according to the
planned schedules. The most modern methods used for project management is Gantt
chart and Critical Path Method(CPM). The Gnatt chart allows calculating the timeline
of the project with every phase of the project, when to start and when to move on with
next phase with every task being allocated to the responsible team member. CPM is
used  for  identification  of  specific  critical  tasks  that  has  effects  on  the  timeline  of  the
project. In larger organisations there are experienced mangers working on each phase of
x 93/42/EEC on Medical devices (MDD)
x 98/79/EC on in vitro diagnostic Medical devices (IVDD)
x 90/385/EEC on active implantable Medical devices (AIMDD)
x 2003/32/EC for Medical devices utilizing tissues or derivatives
originating from animals susceptible for TSE
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the project while in smaller organisations individuals have to take more responsibility in
completing the tasks. Since every Medical product development is allotted with limited
budgets, managers have to formulate both success and failure scenarios by calculating
the risks involved during NPD process.[17]
3.8. Outsourcing the Product Development
Outsourcing of Biomedical Wearable and Implantable devices can be done at various
stages of product development:
x Pre-clinical trials and Clinical trials: for animal testing the companies have to in-
form the regulatory bodies the address of the animal testing laboratories and human
trial care centres such as Clinical Research Organisation(CRO). While testing the
device, laboratories have to adhere to the compliance of the concerned regulatory
bodies. The regulatory bodies, IACUC, and IRB shall audit the laboratory and then
approve the protocols for the trials. Outsourcing clinical trials predominately reduc-
es time in recruiting the human subjects and makes the product development process
quicker due to expertise.
x Manufacturing process: SME’s who have less expertise in manufacturing a product
in  accordance to guidelines of regulatory bodies or problems of capital to establish
a manufacturing unit can outsource the device who already are in compliance with
regulatory agencies. Sometimes larger companies may outsource the production of
the Medical devices in other geographic regions. But there are certain risks of IP as-
sociated for outsourcing the manufacturing of the product. A company whose device
is novel, highly complex, and expensive, it is better to outsource only certain parts
of the device as know-how can be disseminated to other industry players through
contractors. Contrary, if the risk of IP of the device is low, then it is better idea to
outsource the manufacturing of the device. Personnel’s from the company should be
appointed to communicate with the outsource companies to monitor the process and
make sure that the production process is adhered to regulatory compliance. Figure
3.14 is the matrix that allows mangers to make decision of outsourcing the produc-
tion process.
Figure 3.14. Outsource decision making matrix [17].
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3.9. Manufacturing
The manufacturing of Biomedical Wearable and Implantable devices is transition phase
from NPD to large scale production after undergoing pre-clinical trials, clinical trials,
and approval from regulatory bodies for production in large scale. This means that the
device is safe to be used on humans and ready for the production in large scale. Some-
times the device that has been developed in laboratories under small R&D studies may
not be feasible at the time of technology transfer from laboratory to production because
of different set of parameters and controls in laboratory and production process. The
laboratories look for scientific evidence, innovation, reliability, and predictability while
the production process involves reduction of defection per thousand devices made, re-
producibility of the process, adhering to Good Manufacturing Practices(GMP), and oth-
er international standards. Technology transfer from laboratory to production control
can be failure because:
x lack of capital for mass production
x cultural differences between R&D and operation personnel’s
x lack of communication between R&D and operation personnel’s
x lack of ownership between R&D and operation personnel’s
x market is very bleak for the device or better product is already available
x lack of proper Supply Chain Management(SCM)
x device not feasible for mass production
During NPD process, companies have to involve multi-disciplinary teams and start
planning for production control. Moreover, the design of the device should be sealed
completely before entering the clinical trials as shown in figure 3.12. For better technol-
ogy transfer, companies should start preparing documentation, look for distributors,
involve R&D and operation personnel’s together, marketing should be done rigorously
for profits in future, and search for right suppliers and sub-contractors etc.
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Figure 3.15. Manufacturing scale-up of Biomedical Implants and Wearable Devices.
For scaling up the production units, companies can decided if the production should
be down in house or to be contracted. If contracted, companies have to re-consider some
critical factors as explained in figure 3.14. Many SME’s approach Contract Manufactur-
ing Organisations(CMO’s) until clinical trials, once approval is obtained these compa-
nies build their own production process or can decide in licensing the manufacturing
process to CMO’s. Companies have to make a decision in manufacturing process either
in-house build or giving to contractors depending on the market size, company strate-
gies, and company competence. Companies have to establish Standard Operating Pro-
cedures(SOP’s) which are mandatory for production and process control as per regula-
tory compliance and international standards. Suppliers and contractors should be select-
ed based on their credentials in compliance with the regulatory agencies. The suppliers
have to strictly adopt the design specifications as agreed mutually between the manufac-
turer and supplier. Companies have to audit the supplier/contractor manufacturing units
for quality and check if they are adhering to regulatory standards. Companies should
reject the suppliers/contractors if they have found to supply low quality materials, or
any deviation from the manufacturer’s requirements.
3.9.1. Demand-based Manufacturing
Demand-based manufacturing is the term used for designing a Biomedical Wearable or
Implantable device to the specifications of the clinicians or surgeons depending upon
the condition and requirement of the patient. Most of the Medical companies still manu-
facture the product traditionally using standard sizes, for instance orthopaedic and den-
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tal Implants; due to advance in technology many niche companies are coming up new
ways to meet the demand of customer’s specifications. Due to standard sizes, surgeons
have to alter the Implantable devices in the body due to which the life cycle of the prod-
uct can decrease. Most of the younger patients who are undergoing orthopaedic Im-
plants tend to have limited physical activity due to the limitations in the Implants. Con-
sidering these factors, manufacturers have to develop and design according to the ana-
tomical structure of these patients. In case of Wearable devices, computing algorithms
and design of the device can be manufactured as per the patient’s parameters and condi-
tion of disease. The term generally used for demand-based manufacturing is “Addictive
manufacturing”. Andy Christensen, President and Owner, Medical Modelling Inc states
that CAGR for orthopaedic Implants  grows at 13.5% between the periods 2012 to 2017
and the market value for such products shall raise to $3.5 billion in 2017[40]. Moreover,
patients are allergic to certain substance in the Implants; using addictive manufacturing
the materials suited for the patient can be applicable. Figure 3.15 outlines the basic ap-
proach of demand-based manufacturing. Advantages in using demand-based manufac-
turing are [41]:
x design of Implant is according to specifications as per anatomy and pathology
x disappearance of stress shielding effect(bone requires constant stress or load for
proper bone remodelling, in case of standard orthopaedic Implants the stress is ab-
sorbed by the hard element Implants which has side-effect on bone remodelling,
where the bone material is reabsorbed into the body making the bone more porous
and not holding the implant[42]
x avoiding carpentry job by the orthopaedic surgeons for manual adjustment
x ability to design complex shapes
x minimizing inventory which in turn reduces obsolete devices
x manufacture what is required [43]
Whilst there are huge benefits for this kind of niche marketing, there are challenges
to be met both from the manufacturers, the clinical healthcare providers, and the regula-
tory authorities which are:
x improvement in technology for 3D imaging and designing process
x infrastructure across the stakeholders
x up-link and down-link communication between the parties
x pricing of the Biomedical device
x competitive standard Biomedical devices with cheaper prices
x JIT(just in time) approach and SCM
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Figure 3.15. Outline of demand-based manufacturing.
3.10. Reimbursement, Sales, and Distribution
Companies planning to market the device should also consider the Healthcare providers
and payers. Healthcare providers and payers play an important role for the reimburse-
ment of device and increase in sales. Also Gross Domestic Product(GDP) and govern-
ment spending on Healthcare system have impacts in placing the device in market for
treatment.
In USA, the Healthcare system is complex and involves:
x Medicare System(>65years)
x Medicaid System(low income people)
x Private insurers(<65years)
x Self-Pay(for non-insurers)
x Hospitals and Healthcare providers
x Distributors, Wholesalers
If the Medical device has to enter the market in USA, companies have to influence
the insurance companies to pay for treatment costs, and Healthcare providers to enrol
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their device for treatment by the surgeons or physicians. Sometimes these third parties
may influence the cost price of the device, generating lesser profits to the companies.
Companies can also influence the coverage decision to these third parties by proper
product development planning, education to payers, publishing the articles related to the
product, co-operation between manufacturers and distributors or local wholesalers etc.
The three main components for reimbursement are coverage, coding, and payment.
In coverage phase, the insurance companies who are going to pay for the treatment re-
quire proof on the clinical evaluation of the device which is more effective than existing
treatment. The treatment should be listed within the insurance company’s catalogue if
the reimbursement has to be done and coverage decision has to be made. Another com-
ponent is entering the treatment in to International Classification of Disease sys-
tem(ICD-9 code) and Healthcare Common Procedure Coding System(HCPCS II) or
Current Procedural Terminology(CPT) as these codes identify the specific treatment
carried out by physicians for the indications. Many hospitals adopt this coding system to
capture the diagnosis or treatment for administrative transactions and claim the insur-
ance companies. The Biomedical Wearable or Implantable device treatment procedures
have to be enrolled into the existing codes for market potential of the device. If the pro-
cedure is not described into the existing codes then lobbying with certain physician
groups can help to get Not Otherwise Classified(NOC) for application of the device in
the treatment for the indication. But having NOC for the device, the manufacturer and
organisation providing the Healthcare have to work out for billing each time the treat-
ment has been done which may increase reimbursement time to the manufacturer.
Hence, not having CPT code leads to low sales of the Medical device which may ham-
per  the  development  process  of  other  product  lines.  Manufacturers  have  to  decisively
establish strategies at the time of clinical trials with wholesalers, distributors, insurance
companies, and Healthcare providers for reimbursement. For instance, orthopaedic
companies spend $37 on every $100 they earn on sales and marketing [44].
In Finland, companies wanting to sell their products must have CE marking, and al-
so register at Valvira. Valvira is the national supervisory authority for welfare and
health, which can have influence in promoting the sales of device[45]. In England, Na-
tional Health Service(NHS) has influence in procurement of the Medical devices and
other Healthcare services by evaluation of the technology[46]. Also, local wholesalers
can play a major role in promoting the Medical device in private Healthcare providers.
3.11. Unique Device Identification(UDI)
UDI consists of Device Information(DI) such as company address and product identity,
and Product Information(PI) such as shelf life, serial or lot number, manufacturing date,
single use, or sterilised product. The nomenclature used for coding of the device is
Global Medical Device Nomenclature(GMDN). As defined in ISO 15225 standards,
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GMDN has three level structures: device category, generic device group, and device
type. The ambition of GMDN is to provide single naming system to furnish the authori-
ties, Healthcare units, manufacturers, suppliers, and other bodies for the patient safe-
ty[47].  UDI should be created and maintained by the manufacturer for his/her Medical
device, and provide all the necessary information pertaining to the device. The purpose
of UDI for global commercialising of the Medical devices is to facilitate.
x traceability of the device
x to identify the device for distribution and use
x reducing Medical errors
x to capture the statistics of Medical devices[48]
The main challenge of UDI is to integrate all the regulatory authorities and provide
unambiguous identity to the device through Unique Device Identification Data-
base(UDID). Though UDI is still under proposal format, implementation of UDI can
help  the  Medical  device  industries  to  easily  enter  the  market  through  globalisation  of
supply chain, which requires support from politics and other stakeholders. The commu-
nication between different entities in UDI approach is shown in figure 3.16.
Figure 3.16. Outline of UDI approach [49n].
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Quality requirements are mandatory for every Medical device in order to improve the
efficiency and effectiveness, and deliver the product that meets the expectations of the
customers. In current thesis, the quality requirements combined from FDA, EU MDD,
ISO, and IMDRF quality management systems for Biomedical Wearable and Implanta-
ble devices have been discussed. ISO 13485 standards should be adopted by manufac-
tures of Medical device as indicated in QMS for design and production process of Med-
ical devices.
4.1. Documents
There are three documents to be established by the manufacturer during product devel-
opment stages:
x Design History File(DHF): The DHF contains all the records pertaining to design of
the final product such as user needs, design input, design process, design output etc.
x Device Master Record(DHF): The DMR contains all the design methods, specifica-
tion, production process specifications, SOP’s, packaging, labelling, sterilisation,
etc.
x Device  History  Record(DHR):  The  DHR  is  used  at  the  time  of  production  of  the
device, to check if each batch or unit of the device is in accordance with DMR.
4.1.1. Design Control Documents
Design control is the quality system that covers the life cycle of the product during
product development stage, preclinical trials, clinical trials, and post-market stage. The
design controls help the mangers and product developers for more visibility of the prod-
uct at all stages of development process. The design control includes design inputs, de-
sign outputs, design validation, manufacturing process, changes to existing device, la-
belling, sterilisation methods etc.
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Figure 4.1. Design control and quality systems outline.
In the design control document the manufacturer should determine the design and
development stages of the device, including the design transfer activities, and should
ensure clear assignment of individual responsible. The design inputs should address the
performances, safety, regulatory requirements, literature review, and associated risks.
The design output should be in accordance to design inputs, should have information of
purchasing, processing, production, servicing, and safety of the device. The design vali-
dation should address that the device meets the requirements, and identify any further
problems to be solved[50].  DHF should show that the design of the device was devel-
oped in accordance to the planned stages of product development[51].
4.1.2. Device Master Record(DMR)
For each model of the device the DMR file should have the following list of documents:
x Device Specifications(DS)
x Manufacturing Process specifications(MP)
x Quality Assurance procedures and specifications(QA)
x Packaging and Labelling specifications(PL)
x Installation, Maintenance, and Servicing specifications(IMS) [52][53]
A more comprehensive requirement is shown in Appendix1.
4.1.3. Device History Record(DHR)
The manufacturer of the device for the batch or unit shall ensure that the following in-
formation should be included in DHR:
x date of manufacturing
x number of units manufactured
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x number of units released for distribution purpose
x acceptance record showing that the device in production is under strict compliance
as shown in DMR
x traceability/identification/control number
x labelling and sterilisation methods[54]
4.2. Labelling
The intention of labelling is to communicate the safety, operational details, and tracea-
bility of the device. Any printed or graphical matter within the packaging of device
should address the application and identification of the device[55]. For a device, country
specific labelling should be adhered to its format along with the language which is un-
derstood by user population, for example USA labelling should have FDA approved
mark while EU should have CE mark on the device for marketing.[56]
4.2.1. Biomedical Implants
The Biomedical Implants labelling should have the particular details on the package of
the device[55]:
x the device should have the company’s name, address of manufacturer, and its in-
tended purpose. In case if the device is being imported the address of the importer or
in case if the device is manufactured in the importing country then the details of au-
thorised representative in the marketing country.
x indication for which the device can be used
x sufficient information for the user to identify the device
x lot or batch number, serial number, or control number for traceability of the device
x indication of manufacturing date, usable date, and expiry date represented in terms
of year and month
x storage or handling conditions of the package
x warning or precautions of the device
x the intended application of the device and undesirable hazards, risks, or side-effects
x information related to verification for safety and operation of the device after instal-
lation
x information detailing the treatment of the device before application of device, e.g.,
sterilisation, calibration, tailoring of the Implant, final assembly with accessory
components
x indication of sterility of the Implant, and in case during damage of the package extra
information concerning the sterilisation methods to be used or contact information
x indication of single-use of device
x if addictive manufacturing devices, the indications should exclusively state the sin-
gle individual and prescription details
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x indication of risks associated with the Implants
x information regarding the risks associated with reciprocal interference such as elec-
trical interference from electro-surgical devices or magnetic interference from imag-
ing techniques
x precautions at the event of change of function of Implants
x precautions when exposed to environmental conditions such as magnetic field, elec-
trical field, mechanical pressure etc.
x information of medicinal products used along the Implants(combinational device)
x information of any medicinal products to administer along the Implant at the time of
surgery
x precautions for the disposal of the Implants
x degree of accuracy for installation of the Implants
x information concerning the handling of the Implants, such as selecting suitable de-
vices or corresponding accessories or software
x information concerning the trained personnel to install the Implant or any training
required for installation
x contact information of company authority during the adverse event occurrence
4.2.2. Biomedical Wearable Devices
The Biomedical Wearable devices other than stated in the section 3.2.1 should have
additional details as mentioned below[55]:
x intended use of the device
x procedures for installation
x operation principles
x performance indications and specifications
x instructions for operation of the device
x calibration procedures
x manual to change any external components
x precautions for operations
x limitations for the use of device
x hazards and risks related to the device
x service information
x maintenance information
x clinical evaluations for the clinicians
4.2.3. Investigational Device Exemption(IDE)
x clinical protocol document which has details of sponsor, clinical investigators,
monitoring authorities, and procedures
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x if the Implant is used for IDE(investigational device exemption), it should indicate
for clinical purpose only. Example “CAUTION: Investigational Device. Limited by
Federal (or United States) law to investigational use”
x information concerning contra-indications, hazards, risks, adverse effects, warnings
and precautions
x in case for preclinical trials on animal use "CAUTION - Device for investigational
use in laboratory animals or other tests that do not involve human subjects” [55]
4.3. Packaging and Sterilisation
For packaging and sterilisation of Biomedical devices ISO proposes relevant standards,
ISO 11607-1 “Requirements for materials, sterile barrier systems and packaging sys-
tems” and ISO 11607-2 “Validation requirements”. The objective of packaging and ster-
ilisation is to have physical protection, and present the Medical device in an aseptic
manner until the use. Depending upon the state of the Medical device, single or multiple
packaging can be used. For proper packaging and sealing process Installation Qualifica-
tion(IQ), Operational Qualification(OQ), and Performance Qualification(PQ) validating
methods should be used. The proper use of packaging and sterilisation methods should
be justified pertaining to the Medical device such that physical and chemical properties
do not change beyond the threshold limits.
Design development of packaging should be documented and consider many factors
such as customer requirements, sensitivity of the product to external environment, label-
ling of the package, sterilisation compatibility, distribution, handling, and storage envi-
ronments.  Documents  related  to  packaging  system  must  be  retained  for  a  time  period
depending on the competent authorities, expiry date of the device, and for traceability of
the device. The SOP’s used for validation methods, process control methods, and other
quality system methods must be reliable and should be signed by the concerned authori-
ty.
For packaging material the following characteristics should be considered to meet
minimum standard: temperature range, cleanliness, bio-burden, electrostatic conductivi-
ty, pressure range, humidity range, and exposure to sunlight. The materials used for
packaging must be non-leaching, odourless, and impermeable to microorganisms, and
the materials should not have adverse effects on the Medical devices.
The evaluation of sterilisation effects as listed below should be done[57][58][59]:
x physical and chemical properties
x compatibility in regards to sealing process
x shelf-life limitations before and after sterilisation
x microbial barrier
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x toxicity and biocompatibility
According to EU Medical directives for active Implantable devices, the devices
should be packed using non-reusable material and should be sterile at the time of mar-
keting the device. The sterile pack should have the method of sterilisation method used
along with other information details while the sales packaging should contain as said in
section 4.2.1.
4.4. Preclinical Studies
Preclinical studies are determining factor for the safe application of the Biomedical Im-
plants on human subjects in clinical trials and to determine the risks associated with the
Implants. Preclinical studies include study of Biomedical Implants under in-vitro, in-
vivo, and ex-vivo environment. ISO 10993 standard is associated to determine the safe-
ty and efficacy of any Biomedical device. There are overall 20 parts under ISO 10993
standard; where part 1 is associated with in-vitro studies while part 6 is about local ef-
fects after the implantation is done. Though other parts(as shown in appendix 3) of ISO
10993 include various studies to be performed about the risks of Medical devices, in
this chapter the current thesis shall discuss about ISO 10993-1 and ISO 10993-6 briefly.
Figure 4.2 indicates brief outline of preclinical trials.
Figure 4.2. Outline of preclinical trial quality requirements.
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4.4.1. Literature Review
Before starting preclinical studies, literature review should be done extensively for the
biological evaluation of the Biomedical Implants and be verified by the third parties or
external agencies. Performing literature review can minimise the tests and assess the
risks/benefits associated with the Implant. The objective of the literature review should
be legible and a plan is established for the selection and exclusion of the articles to be
reviewed. The assessment of literature documents should be based on similar technolo-
gy  devices,  critical  performance,  design  and  operation  of  the  device,  relevant  animal
testing studies, current Medical practice, and intended use of device in question.[60]
4.4.2. In-vitro Biological Evaluation Process
The in-vitro biological evaluation process should assess the physical and chemical char-
acteristics if the Biomedical Implants intended to use on humans and animals using ex-
isting clinical records, existing toxicology and biological safety data, test procedures in
preclinical trials, and risk management process to determine the hazards. In case any
relevant preclinical and clinical data exists no testing of the device is required as it has
demonstrated the safe history use that is equivalent to the device in question. The risk
management process(ISO-1497) shall take in to consideration of biological hazards for
every material, combined material, and final product. The in-vitro or in-vivo tests shall
be related to the intended purpose of the device and should strictly adhere to Good La-
boratory  Practices(GLP).  In  order  to  minimise  the  preference  of  the  in-vivo  tests,  in-
vitro  tests  should  be  validated,  should  depend  on  the  already  tested  data  of  the  same
Medical device characteristics, and the methods should be reliable and reproducible.
According to ISO 10993-1, Medical Implants are classified into devices which comes in
contact with bones(tissue/bones) and devices which come in contact with blood(blood).
Material characterisation is pivotal step during biological evaluation process. The
manufacturer should address the materials, chemical constituents of the material, and
additional additives used for manufacturing of the device. If the materials, chemicals,
and similar technology process have history of safety and efficacy then biological eval-
uation is not required. Risk management process is mandatory for material characterisa-
tion during biological evaluation. Table 4.1 shows the linkage between the material
characterisation  and  biological  evaluation  in  order  to  take  the  decision  for  the  use  of
such materials and chemicals.
A brief list of biological evaluation tests that should be considered during the evalu-
ation of Biomedical Implant devices in-vitro is shown in table 4.1. And additional set of
evaluation tests might be required depending on Medical devices if stated by regulatory
authorities. The risk assessment for determining hazards should also consider chronic
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toxicity, carcinogenicity, biodegradation, toxicokinetics, immunotoxicity, reproduc-
tive/developmental toxicity or other organ-specific toxicities [60].
Table 4.1. Biological evaluation chart for Biomedical Implants [60].
Evaluation Test
Contact duration: (A-limited(24h),
B-prolonged(>24h to 30days), C-
permanent(>30days))
Tissue/Bone
Medical Im-
plants
Blood related
Medical
Implants
Cytotoxicity
Sanitization
Irritation or
intracutaneous reactivity
Systemic toxicity(acute)
Sub-chronic toxicity(subacute toxicity)
Genotoxicity
Implantation
Haemocompatibility
A
x
x
x
B
x
x
x
x
x
x
C
x
x
x
x
x
x
A
x
x
x
x
x
x
x
B
x
x
x
x
x
x
x
x
C
x
x
x
x
x
x
x
x
4.4.3. In-vivo Biological Evaluation after Implantation
The purpose of preclinical trials is to estimate overall effects of the Implant in the living
environment of animals before testing it on human subjects. Adhering to ISO-10993-2
standards and GLP is necessary for preclinical animal trials. Before the start of biologi-
cal evaluation in animals the protocols should be approved by IACUC and respective
regulatory authorities. For Biomedical Implants smaller animals such as mice, rats,
hamsters, and rabbits are usually preferred, implantation on larger animals such as dogs,
sheep, goats, and pigs should be justified. In most preclinical animal trials smaller ani-
mals are used for short-term testing while larger animals are used for long-term testing.
The time period of testing an implantation depends on short-term or long-term analysis,
non-degradable/non-resorbable or degradable/resorbable Implants, and post-surgery
trauma effects. In general the short-term assessment for non-degradable/non-resorbable
is between 1week to 4weeks, and for long-term assessment it is over 12 weeks. For de-
gradable/resorbable Implants the estimated time period for assessment depends on deg-
radation  time  of  the  Implant.  Prior  to  implantation  of  degradable/resorbable  Implants,
degradation studies should have been done in-vitro. The evaluation of degradation
should be done at various time points:
x when there is no or minimal degradation(1week to 12 weeks after implantation)
x during the occurrence of degradation
x during the tissue restoration or degradation ending point
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The Implant specimens used should be manufactured, processed, and sterilised by
the same methods used for final Implants and follow GMP. The specimen should be
handed-over aseptically for planting the Implant inside the animal with labelled as
"CAUTION - Device for investigational use in laboratory animals or other tests that do
not involve human subjects”[55]. The surgery should be performed under general anaes-
thesia and the size of specimens should be in accordance to ISO 10993-6 standards. In
In order to yield valid evaluation, many Implant devices should be implanted in the an-
imals. The control and test Implants should not be implanted in the same animals. Eval-
uation of Implants should be macroscopic and histopathological(microscopic assess-
ment)  response  as  function  of  time.  Evaluation  should  also  be  done  to  assess  the  re-
sponse to test sample and control sample at the same operating sites in different ani-
mals.
x Macroscopic assessment: During the macroscopic assessment the Implants should
be evaluated depending on the change in structure, tissue reaction towards the Im-
plant,  any  possible  presence  of  degradation  materials,  animal  health  signs  or  reac-
tions towards the placement of Implant, and macro-photography should be docu-
mented.
x Microscopic assessment: The microscopic assessment includes the histological
evaluation in regards to the Implant. The parameters to be recorded are extent of fi-
brosis(layer in mm), inflammation, degeneration of tissue morphology, necrosis,
other tissue alterations, tissue growth levels. For degradable/resorbable Implants in-
termediate levels, near completion of material, and residual debris of Implant should
be presented in tissue samples, and for non-degradable/non-resorbable Implants in
bone the interface between tissue and bone should be examined. Any adverse histo-
logical responses should be presented in photomicrograph.[60]
4.5. Clinical Studies
Clinical studies for Biomedical Implants are more complex when compared to clinical
studies in Biomedical Wearable devices, because Implants are used within the living
environment of the human body while Biomedical Wearable devices are used for diag-
nosis, or monitoring, or mitigation of disease, or treatment for a disease that have influ-
ence(results) for clinicians towards the care of the patient from external environment. In
clinical studies of Implants the safety, efficacy, and performance are measured while in
Wearable devices sensitive, accuracy, and other measurement characteristics are meas-
ured. Though the below sections are more applicable for Implantable devices, some of
the quality requirements in clinical studies can be also applied for Wearable devices.
4.5.1. Clinical Investigation Plan(CIP)
The objective of the clinical investigation is to determine the safety, efficacy, and accu-
racy of the Medical device that is going to be placed in the market and evaluates its in-
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tended purpose. In order to start clinical trial of the device a proper CIP should be
framed with objective and goal of the clinical investigation. The general requirements
have been discussed in chapter 5 under Good Clinical Practices(GCP) as per ISO
14155-1:2003. The CIP should have details(ISO 14155-2:2003) of:
x objective of the clinical investigation
x end points to assess the objective of the clinical investigation
x stages of clinical trials
x follow up time period and adverse events reporting
x mode of recruitment of the subjects, identification of the subjects for clinical trials
x anticipated risk analysis during clinical trials(ISO 14971)
x residual risks after placing the Biomedical Implant in the patient[61]
x control groups to be tested
x inclusion and exclusion criteria of the subjects
x measurement variables, statistical methods, pass/fail criteria of the tests
x subject identification procedures
The  CIP  shall  have  names  and  addresses  of  the  sponsor,  and  patient  management
personnel’s should be clearly stated. The sponsor along with the clinical investigators
and coordinators shall agree to the CIP and sign the document with date and if any
changes are made to the CIP all the parties should agree and the document should be
approved. The CIP document should also address the monitoring path and data verifica-
tion methods with database management, data verification, data analytic methods, data
storage, and data archiving. The CIP shall also include manufacture's name of the Im-
plant, Implant identification number, and software details if used for identification and
traceability. The CIP should also include indications and contra-indications, material
and medicinal products used in Implants, sterilisation methods, storage and handling
details, surgical procedures and training methods for the application of the Implant.
The CIP should include a strong justification for use on human subjects through pre-
clinical evaluation and literature data. The pre-clinical evaluation should have summary
of  all  the  tests  that  have  carried  on  the  Implant.  For  adverse  reporting,  the  document
should have contact details of the responsible personnel details. The document should
have  details  of  foreseeable  adverse  events  and  their  effects,  reporting  procedures  to
sponsor, regulatory agencies, and ethical committee(IRB).[62]
4.5.2. Clinical Investigation
Once CIP is documented the clinical investigation is approached to assess the safety and
efficacy of the Implant in the human subjects. The clinical investigations should be car-
ried on unknown risks of the Implant beyond the literature studies, available clinical
data, post-market studies, and adverse event reports. The data generated through clinical
investigation is used for clinical evaluation of safety and efficacy of the device in hu-
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man subjects. Risk management process should be carried out to determine the residual
risks of the Implants as per ISO 14971 standards. The clinical investigation design
should be done according to intended purpose of the device in question, considering
subject population, dosage levels(in case medicinal product used in Implants), clinical
end points, analysis methods for clinical evaluation, and statistical approach. Also, the
clinical investigation design should consider ethical requirements to safeguard the hu-
man subjects. GCP(ISO 14155) should be adopted during the clinical investigation. The
final document of clinical investigation should have data pertained during clinical inves-
tigation on human subjects for conformity assessment of the Implant.[61]
4.5.3. Clinical Evaluation
During clinical evaluation, the data acquired through clinical investigation is used to
assess the risk/benefit ratio, safety, efficacy, and performance of the Implants for human
use. For clinical evaluation of the Implant a well-qualified evaluator should be adopted,
and justification is required for the choice of evaluator in regards to the implanted de-
vice technology, application, and treatment knowledge. The clinical evaluation should
be  assessed  throughout  the  life  cycle  of  the  Implant  from clinical  trial  stages  to  post-
marketing stage for continuously assessing the safety of the device, and this data must
be inputted to risk management for any changes in the Implants to control the risks.
Clinical evaluation can be done using:
x data obtained through literature search
x data obtained from previous clinical investigation studies
x date obtained through clinical investigation of the Implant
x data obtained through identical Implant using same material or technology
And by using the data as mentioned above, a comprehensive decision can be made if
there is sufficient evidence for conformity of the device or further data should be ac-
quired through clinical investigation
Evaluator should assess the selection criteria for published articles/reports related to
Implant as these articles become part of clinical evaluation. For data obtained for the
similar devices in the market, the data should have clinical evaluation results, post-
market surveillance data for residual risks, adverse events, cohort studies, and other
clinically relevant data. Once the data is generated from various sources and the clinical
investigation results, the evaluator should assess the benefits and limitations of clinical
data(appraisal of clinical data) for demonstration of safety, efficacy, performance, and
intended use of the Implant.  Once clinical data is appraised and relevant clinical eval-
uation should show:
x that the Implant is working as intended by the manufacturer and claims made about
the safety and efficacy of the Implant
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x  that the clinical data gathered from sources is relevant for the safety of the device
for human  use
x that the benefits are outnumbered compared to the risks associated with the Implant
[63]
4.5.4. Post Market Clinical Follow up(PMCF)
PMCF should be conducted according to jurisdiction of regulatory affairs or competent
authorities. PCMF is performed on the human subjects who have undergone the clinical
trials. The PMCF should use appropriate methods to draw the end points and report of
adverse events. PMCF documentation should have related clinical trial questions, objec-
tives, and end points. To address the clinical safety and clinical performance of the de-
vice the residual risks should be identified and risk controls should be documented. The
study plan of PMCF should include:
x number of clinical trial subjects
x subject inclusion or exclusion criteria
x justification of study design and use of control groups
x appoint of investigators and study sites
x endpoints and statistical methods
x time period of follow-up
x justification for termination of clinical trials
x quality measures undertaken
The data gathered from PMCF is used as justification for the safety on human sub-
jects.[64]
4.6. Post-market Surveillance
The manufacturer after marketing the device has to do post-market surveillance in order
to  protect  the  safety  of  public  health  and  to  prevent  the  adverse  events  related  to  the
device. An event related to device during the post-market surveillance can occur
through manufacturer or misuse of the device. The adverse event due to the device
through manufacturer may be because of malfunction or deficiency in the performance
of the device, flaws in design, inaccurate labelling or packaging, and not giving enough
information prior to use. Figure 4.3 highlights the post-market surveillance of the Medi-
cal device.
The manufacturer has to report an event:
x if  there  is  flaw  in  the  design  and  cause  serious  injury  or  death  of  the  patient.  For
example, a software error in the pacemaker or premature failure in hip Implants.
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x if the labelling information is given wrong and no proper information has been put
on label for the proper use of the device. For example, the label of caution is placed
in inside packaging rather outside packaging
x if the device prematurely fails before the shelf/service life. For example, the service
life of hip Implant as stated by manufacturer is around 15 years, and if the Implant
fails before the service life, the event has to be reported
x if the device is being used against the intended purpose as labelled by the manufac-
turer
x in case of death caused due to mistake caused by doctor
The manufacturer no need to report of the adverse event:
x if already existing side effects are known upon the use of the device
x if adverse event occurred due to patient condition not related to the device. For ex-
ample hip Implant failed due to osteoporosis.
x if the manufacturer has taken proper control procedures against the malfunctioning
of the device. For example, one of the ECG sensor failed to gather the signal and the
device has alarmed the user, but still the user did not act upon the warning and led to
injury or death.
x in case if the advisory notice has been sent to all the Healthcare providers for the re-
call or not to be used purpose and still the device has been used
The adverse events have to be reported to National Competent Authorities(NCA) in
30days and for unanticipated deaths the event has to be reported immediately. In USA
the adverse event should be reported to FDA, while in Finland it has to be reported to
Valvira and VTT(Notified body). The report should have information of device manu-
facturer, operator of the device at the time of adverse event, single use / reusable type of
device, current device location or disposition, patient information, and device approval
information(authority who approved the device). [65]
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Figure 4.3. Reporting of post-market surveillance.
4.7. Wearable Devices
Though quality requirements are discussed inclusively for both Biomedical Wearable
and Implantable devices, the following quality requirements are exclusive for Biomedi-
cal Wearable devices. FDA states that “A Medical device data system (MDDS) is a de-
vice that is intended to provide one or more of the following uses, without controlling or
altering the functions or parameters of any connected Medical devices:
x the electronic transfer of Medical device data
x the electronic storage of Medical device data
x the electronic conversion of Medical device data from one format to another format
in accordance with a preset specification
x the electronic display of Medical device data.
A MDDS may include software, electronic or electrical hardware such as a physical
communications medium (including wireless hardware), modems, interfaces, and a
communications protocol. This identification does not include devices intended to be
used in connection with active patient monitoring”[38]
 Most of the Biomedical Wearable devices are related to physiological state or con-
genital abnormality. Wearable devices should be manufactured in such a way to reduce
the risk of infection, for ease of handling the device, and to avoid leakage of device.
Since most of the Wearable devices interact with other devices, the performance of the
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device should not be impaired. The Wearable devices should be designed in such a
manner as:
x to reduce the risk of physical features
x effects of foreseeable effects of external environment such as magnetic fields, elec-
trical fields, temperature changes, pressure changes etc.
x to avoid risks of explosion or fire
x to facilitate the safe disposal of the device
x the display , measurements, or monitoring scales/indicators should follow ergonom-
ic principles
x to show accuracy and stability of the measurements, and the values as per the coun-
try competent authorities
x to design, to be manufactured, and packaged to minimize the effects of the radiation
x to design instruments emitting radiation's as not to have any effects on users, or con-
trolling or adjustment of radiation should be adopted
x to show repeatability, reliability, and intended performance for the software used in
the device
x the information supplied by manufacturer should adequately discuss about the safe-
ty, proper user instructions(including version number), and training of the device
[59]
4.8. Risk Management of Medical Devices
Risk management has to be adapted to all Biomedical Wearable and Implantable devic-
es at all stages of life cycle of the device in accordance to ISO 14971 standards. Risk
analysis can be done using the published data of predicate devices already available in
the market. Risk management is of four distinctive features that the manufacturer has to
identify the hazards associated:
x risk analysis
x risk evaluation
x risk control
x post-production adverse events
The  risk  management  have  to  document  the  scope  of  risks  associated  with  the  de-
vice using the predicate devices, international standards, and country related standards.
It is also responsible to allot personnel’s to work on risk management activities at regu-
lar intervals of time for assessing the risks of the device. The management should pre-
pare risk management plan associated with particular Biomedical Wearable or Implant-
able device at all stages of the lifecycle of the device and to review the acceptable crite-
ria of risks for the device. The management should record all the risk management ac-
tivities and plans to reduce the risk of the device.
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During risk analysis of the device, the management should estimate the foreseeable
use of the device and list the characteristics that can affect the safety of the device. In
addition, the manufacturer has to estimate the foreseeable hazards for the device in both
normal and faulty conditions. After identifying the related hazards the management has
to estimate the risk associated with each hazard. Estimating risks can be done using
qualitative and quantitative analysis, or information from external sources such as pub-
lished standards from various international organisations, scientific data, existing predi-
cate devices, clinical trials, post production reports, and opinions of experts and external
quality assessment organisations.
Once risks associated for the hazards have been identified, the management has to
evaluate the design and production process of the device. Once evaluated the manage-
ment have to implement risk control measures at all stages of lifecycle of the device.
Once the control measures are taken, the risk control verification has to be done and
should be well documented. If any residual risks are associated with the device, control
measures have to be taken and should be implemented. Moreover, the management
should analyse if the overall residual risks are acceptable for the device for its intended
purpose, if not the management have to re-evaluate the risks and take control measures.
The post production data obtained through post-market surveillance is mandatory in all
the regulatory compliance, it helps the manufacturers know if there are any unforeseea-
ble risks of the device[66] . More information about the hazards associated with the
Biomedical Wearable and Implantable devices are shown in appendix2.
Figure 4.4. Risk management process of a Medical devices.
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4.9. Validation of Standalone Software
Another important aspect to consider about the active Implants and Wearable device is
standalone software. Any software or computer program that is designed to incorporate
the Implant or Wearable device that is used for treatment or monitoring the performance
or used for decision making by the clinicians comes under standalone software for regu-
latory process. Standalone devices should be approved from the regulatory authorities
such as:
x software in active therapeutic devices, which are intended to direct energy source or
exchange data from inside the body. Example include monitoring of pacemakers
which can transmit data
x software  intending  to  measure  the  vital  physiological  state  of  the  organs.  Example
include monitoring of the heart rate
x software’s used for designing the Biomedical Wearable and Implantable devices.
Example include hip implant designing software
x software algorithms that are used for monitoring, diagnosis, treatment, or prognosis
of individual patient
x pre-hospital ECG system that are used to transmit data to doctor at remote location
x health care environment
x telemedicine software’s for monitoring of patients by healthcare units from remote
locations [67]
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This chapter includes good practices to be practiced by companies and research organi-
sations to show that the product is safe and efficacy, and results are repeatable for the
approval of the regulatory bodies and process followed are in correspondence to regula-
tory compliance.
5.1. Good Laboratory Practices(GLP)
The purpose of GLP is to assure that the management of the companies or research or-
ganisation have adopted quality system to ensure that non-clinical tests are validated,
uniform, reproducible, and consistent. Companies selling products in USA or EU re-
quire that they follow strict GLP standards as prescribed by FDA or EU notified agen-
cies[68n] as non-clinical laboratory studies support applications for further research
development in clinical trials or marketing of device[70n]. In addition, clinical trials and
manufacturing of the products requires the approval in non-clinical studies, organisation
adhering to these GLP’s can reduce time and effort as it makes easy for the regulatory
bodies to audit and approve the tests. GLP’s key elements include study director, Quali-
ty  Assurance  Unit(QAU),  SOP’s,  reagents  and  solutions,  test  and  control  articles,  raw
data, storage and archiving, personnel, equipment validation, and statistical procedures
for data evaluation. [68][69][70]
5.1.1. Organisation and Personnel
The management or sponsor should allocate study director and trained personnel’s for
the non-clinical studies. Study director is responsible for the conduct of the non-clinical
analysis, documentation, and presentation of results[69]. The individuals working in the
preclinical/clinical studies should be experienced and should be allotted the job that is
fulfilled on time. Individuals working in laboratory should adhere to protocols and be
sanitised. Individual personnel suffering from illness should be excluded if there is im-
pact on tests.[69][70]
5.1.2. Quality Assurance Unit(QAU)
QAU is an internal control function team that should assure the management that the
facilities, equipment, personnel, methods, practice, records, and controls are in con-
formance as per the regulatory bodies[69][70]. The laboratory management should pre-
pare written procedures that should be carried out by QAU, and should submit the pro-
cedures to regulatory bodies when notified. QAU should update the management of the
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inspections carried out as per schedule and duly report any problems encountered during
the non-clinical studies. The main responsibilities of QAU include:
x to maintain the copy of master file containing all the tests being conducted at the test
facility containing information about nature of study, initiated date, status of the
study, sponsor identity, and study director.
x to maintain written procedures pertaining to QAU
x to periodically inspect the undergoing tests
x to submit written document to management about the progress of the study
x to find out if any deviations from the SOP’s carried on with proper authorization
x to review the final report and to check if the personnel’s followed as per the proto-
cols
x to audit and validate laboratory equipment [69][70]
5.1.3. Facilities
Facilities for laboratory testing should be of suitable size for proper laboratory tests.
There should be enough degree of separation between the tests, so in case of adverse
events the other tests should not be disturbed or contaminated. The facilities of animal
care should have enough rooms and animals should be separated as per the tests carried
out. There should be separate areas for diagnosis and treatment of animals. Animal fa-
cilities should also have proper disposal of wastes so contamination is minimised. Facil-
ities should also provide separate areas for storage and mixing to avoid contamination.
SOP’s shall be established and should be reviewed to ensure the quality and integri-
ty of the study. The SOP’s should have unique number and revision number. Deviation
from SOP must be authorised by the study director.[69]
The reagents and solutions used in laboratory should be labelled with identity, con-
centration, storage temperatures, and expiration date [70]
5.1.4. Equipment
Equipment’s used in laboratory tests should be of appropriate design and should allocate
proper space for cleaning and maintenance. Equipment’s should be validated as per the
laboratory  protocols.  Copy  of  SOP’s  of  each  equipment  should  be  placed  next  to  the
equipment which contains procedures for maintenance, application, cleanings, and trou-
bleshooting. Records of maintenance should be written and should be provided when
required for auditing.
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5.1.5. Test and Control Articles
Test article means any drug or biologic product for human use while Control article
means any drug or biologic product other than test article that is administered during the
course of non-clinical studies established for the comparison with test article [71].
Procedures should be documented for each batch of test control articles to determine
the identity, strength, purity, composition, and other characteristics. Also, synthesis and
fabrication methods should be documented. These documents must be submitted to reg-
ulatory bodies for inspection. Storage container used for the test or control articles must
be labelled by name, batch number,  chemical extract number, expiration date and any if
applicable[69][70]. Also, stability of these articles should be performed before the start
of studies and during the studies for every batch of test control articles[70].
5.1.6. Protocol for conduct of a Non-clinical Laboratory Study
The study director should prepare the protocols for every test being conducted. The in-
formation in protocol should include:
x title and objective of the studies
x identification of test and control articles
x sponsors details
x testing design, description of materials and chemicals used, and dosage levels
should be indicated in country specific units as required by regulatory authorities
x statistical methods adhered
x approval of study director for the protocols, and sign of study director if any chang-
es are made to the protocol[70]
5.1.7. Records and Reports
The final report of each laboratory tests should include name and address of facility,
objectives and procedures, statistical procedures for data evaluation, description of ma-
terials and drugs used, any adverse events, study director and individuals involved,
signed and dated reports, location of reports, specimens and raw data, and the sign of
study director. In addition, the raw data, documentation, protocols of the test, and spec-
imens used for the test should be stored with few exceptional in orderly manner and
should be accessible only by specific individuals.[70]
5.1.8. Disqualifications of Testing Facilities
The sponsor should intimidate the regulatory bodies about the testing facilities. On audi-
tion the regulatory agency can disqualify the testing facility for not complying with the
regulations, any change in results, or in case it is understood that the testing facility may
adverse effect the results.[70]
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5.2. Good Clinical Practices(GCP)
The purpose of GCP is to assure the public that the rights, safety and wellbeing of hu-
man subjects involved are protected[72]. The goals of GCP are also to provide reliable
data to the review board and the regulatory agencies pertaining to clear the Medical de-
vice in a qualitative environment. The International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use(ICH)
adopted GCP, whose task is to provide unified standards to the EU, United states, and
Japan  and then later followed by other countries. The ISO 14155 standards are adopted
for GCP as general requirements for clinical investigation [73]. The guidelines provided
by ICH is set of instructions to the companies generating clinical data to be submitted to
the regulatory agencies[74]. In this section brief information about GCP has been cov-
ered which are taken from ICH standard document other than discussed in GLP section.
[72][74]
5.2.1. Duties of Institutional Review Board(IRB)
The  principles  of  ICH  covers  the  ethics  in  clinical  trials,  submitting  a  comprehensive
report to IRB or Independent Ethics Committee(IEC) about the benefits and risks in-
volved in the investigational drug for the proposal of clinical trial, adopting the compli-
ance of IRB/IEC, educating and training the individuals involved in clinical trials such
as investigators, monitoring agents, physicians, human subjects etc., storage of records
and data concerning to the clinical trials,  maintaining the confidentiality of the reports
concerned to human subjects, and adopting GMP to the investigational products.[74]
The responsibilities of the IRB/IEC include:
x to see that the sponsors adhere to the clinical ethics of the human subjects
x to obtain the documents of trial protocol, consent forms, information provided to the
subjects, Investigator's Brochure (IB), safety and quality information, investigator's
information. In addition after obtaining these documents, IRB/IEC should state its
views on conduction of clinical trials is favourable or unfavourable, modifications to
the clinical trial protocol or any amendments if required, or termination of clinical
trials
x to audit the clinical trials in intervals and determine to continue or terminate
x to store the records for a period or 3 years or longer and be shared with regulatory
authorities on request [74]
5.2.2. Investigator
The investigator who is going to perform clinical trials should be qualified and experi-
enced person whose responsibilities include adopting the clinical trial protocol and hav-
ing knowledge of GCP and regulatory requirements. The investigator also should recruit
well qualified persons responsible for clinical trials and inform them about the proto-
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cols. The investigator should adhere to the trial time period. The investigator should
monitor the human subjects and be responsible and provide Medical care if in case of
adverse events and also should ascertain the reasons if the human subject is withdraw-
ing  from  trial  though  the  human  subject  has  rights  to  withdraw  from  the  trials  at  any
given time.
Investigator should also be responsible for communication with IRB/IEC and sub-
mit the documents when asked by the authorities. The investigator should also inform
the IRB/IEC bodies of any changes or amendments to the clinical protocol and justify
the reasons. The investigators should adapt strictly to the clinical protocols agreed by
the sponsors and regulatory authorities and should not deviate from the protocol. If any
deviation from the actual protocols the investigator should document and justify the
reasons.
In addition the responsibilities of investigator include accountability of investiga-
tional products. The investigator should record the investigational products used, and
follow the instructions provided by sponsor for application and storage. The investigator
is also responsible for talking to human subject physicians if the protocol de-
notes(blinding).
The investigator responsibilities also include to submit the progress reports to the
IRB/IEC frequently as requested and reports about Serious Adverse Events(SAEs) im-
mediately. [74]
5.2.3. Sponsor
The sponsor is responsible for quality assurance and control of the clinical trials. The
sponsor should provide enough information to the investigators or Contract Research
Organisations(CRO’s) to implement the clinical trials. The sponsor can recruit Medical
experts to prepare the clinical trial protocols and involve them at every stage of clinical
trials.  The  sponsor  can  also  assign  the  Independent  Data-Monitoring  Committee
(IDMC) to monitor the progress. The sponsor is also responsible for financing the clini-
cal trials and human subjects involved.
The sponsor should notify the regulatory bodies about the information of investiga-
tors  and  submit  the  reports  when  asked  by  these  authorities.  The  sponsor  should  also
submit data that pertains to non-clinical studies to support the start of clinical trials. The
sponsor should assure that the investigational products manufactured on small scale
follow GMP and show efficacy. The sponsor also should provide information on how
the investigational products are packaged and stored for the human trials.
The sponsor should share adequate information to the investigators such as proto-
cols, SOP’s, Investigator’s Brochure(IB) etc. before the start of the trial. The sponsor
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can allocate auditors who are independent of clinical trials to audit the progress of hu-
man trials. The auditors should prepare a report of their findings carried out by investi-
gators and the report should be submitted to the regulatory authorities when re-
quired.[74]
5.2.4. Clinical Trial Protocol and Amendments
Clinical trial protocol is a document which states the objective(s), design, methodology,
statistical considerations, and organisation of a trial[74].  The document contains the
trial design process, number of human subjects to be tested, SOP’s to the investigators,
dosage levels, duration and sequence of trials, and storage, packaging, and labelling of
investigational products.
The protocol should also justify the selection and exclusion criteria of human sub-
jects, terminating of trial for any reasons, and assessment of efficacy and safety. In addi-
tion, the document should state what kind of statistical approaches are imbibed during
the trial process. [74]
5.2.5. Investigator’s Brochure
IB is a document that presents clinical and non-clinical data to the investigator's and
other personnel’s involved during the investigational product. The IB should support
enough non-clinical data for the understanding of persons involved in clinical trials.
While preparing the IB the sponsor has to involve medically qualified persons. Also,
sponsor should be responsible to update IB annually[74].
5.3. Good Manufacturing Practices(GMP)
GLP and GCP which predates GMP analyse toxicity, stability, and drug development
activities of individual components and whole investigational product while GMP’s
help during producing mass or bulk investigational products and final products with
stability, consistency and quality to ensure that good quality Medical devices are mar-
keted to the public. Biomedical Implants which are combinational devices have to un-
dergo both drug and Medical device GMP’s while Wearable devices needs to adopt
Medical device GMP’s. Drug companies in USA should adopt part 211, current Good
Manufacturing Practices(cGMP) while Medical device companies marketing in USA
should adopt part 820, Quality System Regulations(QSR). Also there are available
WHO GMP’s which are being adopted by several countries while companies in EU
adopt EU-GMP. While few of the key elements have been discussed in the GLP’s the
most important aspects of GMP’s are validation, design controls, Installation Qualifica-
tion(IQ) and Operational Qualification(OQ), method validation, on-going performance,
data security, integrity, traceability, and vendor validation[69].
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5.3.1. Validation
Validation is the process of evaluation of products, equipment’s, and analytical methods
used in the manufacturing of the product. Validation is not one time requirement but a
continuous process at various intervals of time to validate the stability of the process
during manufacturing. In validation process the sensitivity and reproducibility is ana-
lysed for the hardware systems, software systems, and analytical methods individually
and combined. SOP’s had to be written for validation process and should be continuous-
ly reviewed in course of time. Personnel validating the process should be educated and
well trained.
Hardware systems used in the process should be validated prior to the use, during
the regular intervals, and after the repair. While computer systems should be validated
in modules and at the end of development process. Analytical methods should be vali-
dated in ideal scenarios and if any parameters are being changed.  It is always a good
practice for the manufacturing managers to have a validation master plan and document
it thoroughly.
5.3.2. Design controls
Medical  devices  coming under  Class  II(Class  IIa  and  Class  IIb  under  EU regulations)
and Class III  should have manufacturing design control documents established. Design
controls  play  an  important  role  in  selecting  the  right  equipment’s,  computer  systems,
and analytical methods. It has impact on business and life cycle of the products. During
the design phase the manufacturing have to make a chart for every equipment, computer
systems, and analytical methods as below:
x selection of facility, environmental selection
x documenting planning phase of equipment’s, computer systems, and analytical
methods
x risk analysis
x technical specification of requirements
x material quality
x vendor selection for material and equipment[69][75]
The design input and output should be validated and documented for the intended
purpose. Any changes in design should be documented and approved before implemen-
tation. DHF should be established and documented for every equipment, computer sys-
tem, and analytical methods[76].
5.3.3. Purchasing Controls
Manufactures who are buying the products or services should ensure that the suppliers,
contractors, and consultants match the quality requirements of the manufacturers and
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strictly adhere to the specifications. Before the purchase, manufactures should thorough-
ly inspect the facility, instruments, and processes followed by the suppliers and contrac-
tors. Any changes made to the process design or changes in the product or services the
supplier or contractor should notify and get approval of the manufacturer[76].
5.3.4. Identification and Traceability
Manufacturers should establish a process to identify the products during the process of
production, distribution, and installation. In order to trace the product after production
each manufacturer has to allocate a unit, lot and batch number[76].
5.3.5. Production and Process Control
Manufacturers should develop, conduct, control, and monitor production processes to
achieve the stability, integrity, and quality of the products. Though deviations are nor-
mal occurrences of the production process manufacturers should establish and maintain
process control procedures to adhere to the specifications[76].  Since Implants are more
prone to contamination, manufacturer should make sure to have procedures for contam-
ination  control.  Proper  validation  of  automated  systems  should  be  documented.  Other
production controls include regular maintenance schedules, inspection of materials and
equipment’s, adjustment of the equipment’s to the specifications, training of personnel
handling the production, environmental controls, and calibration of equipment’s[76].
5.3.6. Acceptance Activities
Manufacturers shall make sure that any material from vendors should be in acceptable
criteria and match the specification. The manufacturer shall inspect, test and then only
confirm for the incoming products for manufacturing and these activities of acceptance
or rejection should be documented. When the materials are in process, the product
should be matching the specifications in each stage of production. Finally, the finished
goods should be verified and tested. Also, after the final product the personnel responsi-
ble should clearly document each every step carried during acceptance activities and
should be signed as these documents should be part of DHR[76].
5.3.7. Corrective and Preventive Action
Manufacturer should ensure that after thorough audits are being done in manufacturing
process, if any non-conformity activities of the product are found shall thereby be rec-
orded, have taken proper action to correct, and prevent the activities to happen again.
For these reasons the manufacturer shall audit analysing processes, work operations,
concessions, quality audit reports, quality records, service records, complaints, returned
product, and other sources of quality data to identify existing and potential causes of
non-conforming product, or other quality problems[75]. The managers should ensure
that the responsible person shall correct the actions. All these audits should be docu-
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mented and should be submitted to regulatory bodies on request or during auditing pro-
cess[76].
5.3.8. Labelling and Packaging Control
Each manufacturer shall make sure that the label printed is legible and shall have right
applications of the product, endpoints, expiration date, control number for traceability,
storage instructions, handling instructions, and other information applied to the product.
Labelling for every product in the manufacturing unit should be stored in right manner
with identification numbers to avoid mix ups, on release of the labels the personnel who
is examining it shall sign and shall be documented in DHR[76]. The packaging material
used on the products should maintain the stability and integrity of the components while
shipping and distribution[76].
5.3.9. Handling, Storage, Distribution, and Installation
The manufacturer shall ensure that the products should not mix up with other products
and prevent contamination while handling as this have adverse effects on entire batch of
products. In addition, manufacturer should ensure proper storage facilities for the prod-
ucts and should prevent mixing up of other products. Also, manufacturer should avoid
distribution of obsolete, deteriorated, or untested product to reach the final customer.
While distributing the product the manufacturer should maintain proper records of the
distributor details such as name of the distributor, control number, batch number, lot
number and identification number of the product, number of quantities distributed,
shipment date, and any other information if applicable by regulatory bodies. Person who
is installing the product should use the product as intended and any deviation from the
intended use shall be responsible for any adverse effects[76].
5.3.10. Record and Servicing
Manufacturer should make sure that the records related to design of the product such as
device master record(DMR) and device history record(DHR) should be thoroughly up-
dated and signed. It includes the design specifications, drugs used, computer systems,
packaging and labelling specifications, quality procedures, audit procedures, SOP’s,
and procedures for IMS. The manufacturer shall maintain the records of complaints
filed by the customers. The complaints should be recorded and processed as per the pro-
cedures; any adverse events in the complaint shall be reviewed and controlled in pro-
duction and process control. The complaint records should be sent to regulatory agen-
cies in regular intervals to safeguard the public[76].
Manufacturer should ensure that the personnel involved in servicing are well trained
and capable to solve the problems. The service records should be well maintained and
shall be reported using statistical approach to the regulatory agencies. The service rec-
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ords should include name of the device served, control number of the device, date of
inspection, personnel serviced the product, and other applicable details.
5.3.11. Combinational Product
The word combinational product is defined as any product which combined with drug
and Medical device or biological product and Medical device. Many companies are
finding new ways to design and market an Implant using combinational products where
drug or biological products are included within the Medical Implant device. However,
confusion exits for the companies regarding the GMP of the combinational products. In
this scenario FDA states that the companies can demonstrate in two ways:
i. Manufacturers can demonstrate both cGMP requirements for drug and quality
regulation for Medical device as per FDA (or)
ii. Manufactures intending to market as drug device should demonstrate cGMP as
well  few of QSR as shown in table 4.1 or manufactures intending to market as
Medical device shall demonstrate QSR and few of cGMP  as shown in table 4.2.
Box 5.1. Product intended to market as drug [77][78].
Box 5.2. Product intended to market as Biomedical device [77][78].
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6.1. FDA vs. EU Approval Authorities
For higher risk devices, the approval process is quite faster in EU on comparison to
FDA approval. This has impact on the health benefits of the public and reimbursement
on the capital spent for the development of the Medical devices as the latest treatments
are not reaching the public in USA. Moreover companies commercialise first in EU than
in USA due to scrutinised regulatory path by FDA. The gap between devices getting
approval for commercialising is three to four years[79] between EU and FDA making
the stakeholders to consider the marketing geographic regions. This is also due to regu-
latory path process where in USA, FDA is a centralised organisation working on differ-
ent Medical devices while in EU, the regulatory path is decentralised manner where the
companies can work with 72 notified bodies(NB) across EU.
The PMA approval period by FDA has been increased by 135%, 12.5 months in
2000 to 29.3 months in 2010, due to increase in repetitive submission by the companies
in the preclinical and clinical evaluation. This has impacted the development of new
devices in USA, which has limited the treatment choices, improved quality of life, and
limited  physician  choices  for  treatment  to  the  patients  in  USA  when  compared  to
EU[79]. The recall rates of the device are significantly same between speedy approval
process of EU when compared to delayed approval process by FDA, despite FDA seek-
ing more information and review time from the companies to safeguard the public
health.
The studies done by Dr Josh Makower, America’s leading Medical entrepreneurs by
interviewing 200 small and medium Medical devices companies indicated that:
x 85% of participants feel EU authorities are more predictable on comparison with
22% for FDA
x 91% of participants feel EU authorities are more likely reasonable on comparison
with 25% for FDA
x 85% of participants found that EU authorities are more transparent on comparison
with 27% for FDA
x while 75% of participants feel experience with EU authorities as excellent on com-
parison to 16% for FDA[80]
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But most recently EU approval process came in to question when 12 of the high risk
Medical devices were approved in EU, while the same devices have been disapproved
in USA which are found to cause serious adverse effects during  clinical evaluation for
approval of FDA and many believed that EU has lower standards for high risk devices
on comparison to FDA PMA approval process[81]. Due to this European Commis-
sion(EC) has made a proposal for PMA just like FDA PMA for Class IIb and Class III
devices, novel technologies, and high risk devices[82].  Table 6.1 shows a comparison
of USA and EU regulations for high risk devices.
Table 6.1. USA vs. EU regulations for high risk devices [81].
EU FDA
Approval Standard Safety of the device, technical
performance, no clinical evi-
dence required
Safety, and clinical evidence
required
Evidence required literature studies, data from
laboratory studies, and small
clinical trials
valid clinical trials
Approval authority Notified bodies(NB) and na-
tional competent authorities
FDA(centralized authority)
post-market and adverse report-
ing transparency
adverse events, and recalls  must
be reported to NB and displayed
for public
adverse events, and recalls  must
be reported to FDA, and is dis-
played for public
Due to extended delayed regulatory process by both FDA and EU there will be less
spending in R&D, decrease in value of smaller companies due to funding and resources,
non-persuasion of risky devices(more opting for less risky devices), and non-availability
of the device to the public for quality life.
6.2. Role of International Medical Device Regulators Fo-
rum(IMDRF)
Due to global nature of trade, Medical companies have real challenge to get approval
from regulatory authorities and go through the time taking repetitive procedures for get-
ting approval of the Medical device across different regulatory authorities. This can
affect the global trade by not making availability of advanced innovative Medical de-
vices to the public, but also extra burden to the companies in terms of reimbursements
and competition. The purpose of IMDRF which was earlier called as Global Harmonisa-
tion Task Force(GHTF), is to harmonise the national standards across the borders to
minimise regulatory barriers, facilitate trade, lowering time to enter the market for inno-
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vative devices, reducing market for substandard products, and access for new Medical
technologies[83]. The challenges of IMDRF is the convergence of all the regulatory
standards to single international standard while still maintaining certain local jurisdic-
tion laws where Medical companies are required to adhere. In order to achieve single
international standard for Medical devices, it requires commitment from governments
and cross border regulatory authorities, involvement of stakeholders at all levels, and
global traceability of  Medical device.
6.3. Complex Medical Technologies
Due to increase in complex technologies used in Medical devices, the approval pro-
cess from regulatory authorities is being more scrutinised and subject to delay in
marketing the technology. The future in Medical technology is combination of both
Implantable and Wearable devices which works together. These devices are far more
efficient and can be used in early detection of cancer, diabetic patients, neuro-
stimulator Implants for epilepsy/paralysed patients, heart disease patients, drug de-
livery procedures for the targeted organ which eliminates side-effects. Medical nano-
technologies using nano-robots/Implantable sensors that can be connected wirelessly
to the wearable devices for communication where the parameters for drug delivering
can be controlled by the physicians, or for monitoring the performance characteris-
tics  of  the  Implantable  device  which  in  turn  sends  collected  data  wirelessly  to  the
physicians. These kind of Medical devices which uses biomaterial’s and electronics,
needs to be encouraged and regulatory authorities needs to define standards and be
prepared for the future Medical technology to reduce the time for approval and com-
panies have to take responsibility to show safety and efficacy of such advance devic-
es. These complex technologies can be used for the diagnostic/treatment of modern
diseases which can increase the life expectancy and quality of life of the public.
6.4. Challenges
6.4.1. Biomedical Implantable Devices
The future of Biomedical Implants is combination of drug delivery with miniaturization
of circuits to target the drug to the specific organ of the body, though challenges exists
in terms of risks, Medical Implants can be used for diagnosis and treatment of the dis-
eases which can give quality life to the public. Due to heavy profits in this area of prod-
uct development companies have to make sure that all the necessary tests are carried out
to ensure the safety and efficacy of the product. Active Medical Implants should consid-
er the durability of the device which has long battery life, biocompatibility in long stay
of the product in the body, and interface between the device and body environment.
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6.4.2. Biomedical Wearable Devices
Biomedical Wearable devices are new entry to the market and regulatory authorities are
still working on the standards. Companies have to concentrate in increasing the sensitiv-
ity and accuracy despite noises generated in patients during movement or physical activ-
ity and the right computing algorithms and hardware systems to detect the disease.
Since Wearable devices are always worn, power consumption and “wear and tear” fac-
tors should be considered for long usage of the device. For Wearable devices used for
transmitting data, companies have to secure the data from hackers as this data is used
for diagnosis/treatment of the patient. Companies and Healthcare units should work
together to integrate the device data into software system of the hospitals. Moreover,
Healthcare units should dedicate resources for monitoring of the patients with Wearable
devices and provide quick treatment.
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7. CONCLUSION
This thesis has extensively focussed on the commercialising and quality requirements of
Biomedical Wearable and Implantable devices by discussing market analysis and strate-
gies, various product development stages of these Biomedical devices, importance of
stakeholders, and future role of harmonising the Biomedical device quality standards by
IMDRF due to global demand of supply chain management and reduction of approval
time by regulatory authorities across border. Further, the thesis has discussed the market
value of these devices and how they can shape and give quality of life to many people
world-wide due its wider applications.
Concurrently due to vast applicability and huge profits involved in the sales of these
devices, company and university researchers are establishing R&D methods for these
devices involving multi-disciplinary teams for safe entry into the market. Though many
of these devices are replacing standard procedures carried out by physicians, challenges
still exists for these devices in terms of risks, accuracy, sensitivity, and stringent re-
quirements by regulatory due to complex technologies adopted in these Biomedical de-
vices. The future prospects of these Biomedical devices are high, both for the compa-
nies and patients, but care must be taken by the companies to thoroughly evaluate the
safety, efficacy, and accuracy, and adhere to the requirements of regulatory systems. At
the same time, regulatory systems should harmonise the standards world-wide while
maintaining minimum regional regulatory requirements for these devices, and govern-
ment organisations should encourage the industries to develop these devices and edu-
cate both the public and doctors for the safer applications of these devices.
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APPENDIX1: DEVICE MASTER RECORD(DMR) REQUIREMENTS
Device Specifications(DS)
Manufacturing Process Specifications(MP)
Quality Assurance Procedures and Specifications(QA)
x procedures and acceptance criteria for
the verification of packaging, labeling,
installation, and servicing activities;
x blank work order forms for recording
inspection/testing activities, traceability,
and other data for device history rec-
ords;
x device release review/evaluation
checklists[52]
x quality system manual (QM)
x quality system operational procedures
(QOP)
x quality system forms (QF)
x process control specifications/charts
x control plans, instructions and ac-
ceptance criteria for incoming, in-
process, and finished device inspection
and testing
x process flow charts
x process/assembly lines diagrams
x equipment, tools, molds
x manufacturing environment speci-
fications
x setup procedures
x operator instructions
x equipment maintenance procedures
x validation reports for special processes
x sterilization specifications, procedures,
and validation reports
x blank work orders, non-conforming
product/process forms, and other report-
ing forms[52]
x product trade and common names
intended uses
x performance characteristics and
theory of operation
x physical characteristics
x environmental limitations, product
stability and storage requirements
x software specifications
x user safety characteristics;
x component, subassembly and assembly
drawings and specifications
x bills of materials (or lists of ingredi-
ents)
x compositions
x formulations
x wiring and piping diagrams[52]
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Packaging and Labelling Specifications(PL)
Installation, Maintenance, and Servicing Specifications(IMS)
x installation, specifications and instructions
x maintenance instructions
x servicing specifications and manuals[52]
x package drawings and specifications
x filling/packaging procedures
x label/labeling drawings
x instruction manuals[52]
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APPENDIX2: ASSOCIATED HAZARDS
Wearable Devices
x non-accuracy and not-repeatable
x electro-magnetic noise
x electricity conducting problems
x erroneous errors
x software or hardware or user operational problems
x wireless transmission problems or data security issues
x inadequate labelling and operating instructions
x non-breathable textile problems
x sensor instability problems
x high temperature problems
x improper re-use and packaging
x improper charging
x water proof problems[66]
Implantable Devices
x Energy Hazards
- Electricity and heat
- mechanical force
- unintended motion
- ionising and non-ionising radiations
- magnetic fields
x Biological Hazards
- bio-incompatibility
- bio-contamination
- degradation, toxicity
-  carcinogenicity
- mutagenicity
- oncogenicity
- pyrogenicity
- allergic
x Environmental Hazards
- electromagnetic fields
- susceptibility to electromagnetic interference
- electromagnetic emissions
- storage or operation outside stated environmental conditions
- incompatibility towards secondary devices
- mechanical damage
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- contamination problems
x incorrect production and process control problems
x lack of correct labelling of device
x insufficient warning of side effects
x inadequate packaging[66]
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APPENDIX3: ISO 10993
Part 1 Evaluation and testing in the risk management process
Part 2 Animal welfare requirements
Part 3 Tests for genotoxicity, carcinogenicity and reproductive toxicity
Part 4 Selection of tests for interactions with blood
Part 5 Tests for in vitro cytotoxicity
Part 6 Tests for local effects after implantation
Part 7 Ethylene oxide sterilization residuals
Part 8 Selection of reference materials
Part 9 Framework for identification and quantification of potential degra-
dation products
Part 10 Tests for irritation and delayed-type hypersensitivity
Part 11 Tests for systemic toxicity
Part 12 Sample preparation and reference materials
Part 13 Identification and quantification of degradation products from pol-
ymeric Medical devices
Part 14 Identification and quantification of degradation products from ce-
ramics
Part 15 Identification and quantification of degradation products from met-
als and alloys
Part 16 Toxicokinetic study design for degradation products and leachables
Part 17 Establishment of allowable limits for leachable substances
Part 18 Chemical characterization of materials
Part 19 Physico-chemical, morphological and topographical characteriza-
tion of materials
Part 20 Principles and methods for immunotoxicology testing of Medical
devices
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APPENDIX4: LIST OF IMPORTANT DOCUMENTS AND STAND-
ARDS
x Council Directive 93/42/EEC of 14 June 1993, concerning Medical devices (MDD)
as amended by Directive 2007/47/EC. [84]
x Council Directive 90/385/EEC of 20 June 1990, on the approximation of the laws of
the Member States relating to active implantable Medical devices (AIMDD).
x Commission Directive 2003/12/EC of 3 February 2003, on the reclassification of
breast Implants in the framework of Directive 93/42/EEC concerning Medical de-
vices (Breast Implant Reclassification Directive).
x Commission Directive 2003/32/EC of 23 April 2003, introducing detailed specifica-
tions as regards the requirements laid down in Council Directive 93/42/EEC with re-
spect to Medical devices manufactured utilizing tissues of animal origin (Animal
Tissues Directive).
x Guide to the Implementation of Directives Based on New Approach and Global Ap-
proach (European Commission).
x European Parliament and Council Directive 94/62/EC of 20 December 1994, on
Packaging and Packaging Waste (PPW).
x Directive 2005/32/EC of the European Parliament and of the Council of 6 July 2005,
x establishing a framework for the setting of Eco design requirements for energy-
using products and amending Council Directive 92/42/EEC and Directives
96/57/EC and 2000/55/EC of the European Parliament and of the Council (EuP Di-
rective).
x Directive 2002/96/EC of the European Parliament and of the Council of 27 January
2003 on waste electrical and electronic equipment (WEEE) - Joint declaration of the
European Parliament, the Council and the Commission relating to Article 9.
x List of European Harmonized Standards (Official Journal of the European Commu-
nities).
x European Commission Europa web site for Medical devices and all guidance docu-
ments.
x ISO 9001: 2008 Quality Management Systems. Requirements.
x ISO 13485: 2003 Medical devices - Quality management systems - Requirements
for regulatory purposes.
x PD ISO/TR 14969: 2004 Medical devices - Quality management systems - Guid-
ance on the application of ISO 13485: 2003.
x ISO 14971: 2009 Medical devices – Application of risk management to Medical
devices.
x EN 12442-1: 2007 Medical devices utilizing animal tissues and their derivatives.
Application of risk management.
x EN 12442-2: 2007 Medical devices utilizing animal tissues and their derivatives.
Controls on sourcing, collection and handling.
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x EN 12442-3: 2007 Medical devices utilizing animal tissues and their derivatives.
Validation of the elimination and/or inactivation of viruses and transmissible spon-
giform encephalopathy (TSE) agents.
x FDA’s Quality System Regulation, Part 820 of 21 CFR (US Code of Federal Regu-
lations).
x FDA’s CDRH web site and all guidance, especially that provided by Device Advice.
x IMDRF. Website: www.imdrf.org
